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Summary
1
2Ocular melanoma is a rare but potentially fatal disease. Radiation therapy pro-
vides a means of both controlling the disease and preserving the eye. One method
of delivering radiation therapy uses radioactive sources held in a plaque temporar-
ily sutured to the eye. This method is widely used but the treatment protocol
varies significantly between institutions. Further, the dose distribution around the
low-energy sources typically used for plaque radiotherapy is highly dependent on
the construction of the sources and the eye plaque. The use of different sources,
eye plaques and dosimetric assumptions precludes straightforward comparison of
treatments between institutions.
The work presented in this thesis is intended to compare the dosimetry and
treatment outcomes for patients treated with eye plaque radiotherapy between 1985
and 2006 at Royal Perth Hospital (RPH) with those of the largest clinical trial of
eye plaque therapy; the Collaborative Ocular Melanoma Study (COMS), and to
identify treatment parameters that significantly affect the outcomes. The findings
would then be used to develop recommendations for eye plaque therapy. To enable
comparison of dosimetry, all doses delivered at RPH were re-calculated with a newly
commissioned treatment planning system (TPS) using specific dosimetric assump-
tions. Doses re-calculated for the COMS with the same assumptions are reported
in the literature. The re-calculated doses indicated that the average dose delivered
in the RPH study was 17% lower than that delivered under the COMS protocol.
The long-term treatment outcomes, specifically the visual outcome, survival and
recurrence of the tumour, for the RPH patients were evaluated. Cumulative in-
cidence models, incorporating the competing risk of death from unrelated causes,
were used to determine the 5-year rate of mortality, of local recurrence and of poor
visual outcome. The relative effects of patient and treatment parameters on the
probability of these treatment outcomes were examined using Cox proportional haz-
ard models. The 5-year mortality rate for the RPH patients of 12% was consistent
with the mortality rate achieved in the COMS. The 5-year rate of recurrence for
the RPH patients was 19%, close to double the 5-year rate of recurrence of 10%
observed for the COMS patients. However, the 5-year rate of poor visual outcome
for the RPH cohort was 28%, significantly lower than the 5-year rate of poor visual
outcome of 49% in the COMS. The difference in treatment outcomes is consistent
with the expectation that a lower dose to the tumour and therefore the surrounding
normal tissue would reduce the probability of both tumour control and complication
of normal tissue. The treatment parameters strongly associated with greater risk of
mortality were the dose rate and the biologically effective dose to the tumour apex.
3The dose to the sclera, at the base of the tumour, strongly predicted the risk of
tumour recurrence. No treatment parameters were found to significantly influence
the visual outcome of the treatment.
The higher rate of local recurrences, which were usually treated by surgical re-
moval of the eye, represent a failure of an aim of the treatment; conservation of
the eye. It was concluded that the prescription dose, and therefore the dose to the
sclera, should be increased to a value consistent with the COMS with the recognition
that the rate of poor visual outcome would also likely increase. The probabilities of
successful prevention of metastasis and of a good visual outcome could be increased
by optimising the biologically effective doses to the tumour and nearby ocular struc-
tures at risk. A shorter treatment time of around four days would deliver a higher
dose rate, and therefore a higher biologically effective dose, to the tumour apex.
Such a treatment regime would be appropriate for patients considered at low risk
of poor visual outcome, as indicated by the distance between the tumour and the
ocular structures at risk. Delivering the same dose to the tumour over a longer pe-
riod, such as six days, would increase the probability of preservation of some useful
vision for patients at high risk of poor visual outcome whilst keeping the probability
of tumour control consistent with that achieved in the COMS.
Chapter 1
Introduction
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1 Introduction 5
1.1 Ocular melanoma
Ocular melanoma is a rare disease, affecting only around 1 in 140 000 people per year
in Australia [1], but an intra-ocular tumour has the potential to metastasize to other
extra-ocular sites. The survival time following metastasis is short; death usually
follows within months of detection of metastases. The biologic activity of ocular
melanoma is highly unpredictable as some tumours remain dormant for years, then
suddenly grow and metastasize [2]. Until around 30 years ago, the standard approach
to treat ocular melanoma was surgical removal of the eye (enucleation). In 1978,
Zimmerman and colleagues published a reappraisal of survival data on patients with
uveal melanoma that suggested enucleation may in fact hasten metastasis [3]. The
publication prompted further research into both the behaviour of ocular melanomas
and treatment options. Treatment of ocular melanoma with radiation therapy was
introduced around 50 years ago and is now routinely used as an alternative means
of controlling the tumour whilst offering the potential to preserve the eye and some
useful vision. The most commonly used system for delivering radiotherapy uses
plaques loaded with radioactive sources. The plaque is sutured to the outer surface
over the eye overlying the tumour and is left in place for around five days.
The technical advances in the development of treatment methods were evaluated
from long-term follow-up of patients but, as treatment and observation criteria and
protocols vary considerably between centres, it is difficult to compare outcomes
and to identify the optimal approach to treat ocular melanoma. The Collaborative
Ocular Melanoma Study (COMS) is a multi-centre, randomised trial conducted in
the USA for small, medium and large ocular tumours. The main purpose of the
COMS is to compare radiotherapy with enucleation with respect to mortality [4].
The initial mortality findings showed that mortality rates between the two treatment
options were consistent. However, as for many multi-centre trials, an objective of
COMS is to establish standard observation and treatment criteria.
Radiation therapy, delivered with eye plaques loaded with radioactive sources,
has been used since 1985 at Royal Perth Hospital in Western Australia. The treat-
ment protocol used at Royal Perth Hospital is quite different to that used in the
COMS and so it is essential to evaluate the long-term outcome of eye plaque therapy
under this protocol. However, transport and scattering of low-energy photons in a
medium is highly dependent on the composition of the medium. The construction of
the eye plaques used at Royal Perth Hospital is very different to that of the COMS
eye plaques and so any meaningful comparison of outcomes requires that all doses
calculations accurately account for the composition and design of eye plaques. The
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frameworks for dosimetry calculations used under both the COMS and at Royal
Perth Hospital were inadequate and so the first part of this project validated and
implemented a sufficiently sophisticated algorithm for dosimetry of eye plaques to
enable comparison of doses for different types of eye plaque. This study then used
the revised dose calculations to investigate the outcomes of patients treated with eye
plaque therapy between 1985 and 2006, to compare indicators of treatment outcome,
such as survival, rate of local recurrence, and visual acuity, with those achieved in
other centres as reported in the literature, and to elucidate factors influencing the
treatment outcome, with the aim of then exploiting these factors to improve the
outcome of future treatments.
1.2 Thesis outline
Following this brief introduction, medical information pertinent to ocular melanoma
is presented in Chapter 2. The anatomy of the eye, the incidence and prognosis of
ocular melanoma and the available treatment options and regimens are discussed.
The findings of several large-scale clinical trials and cohort studies of treatments for
ocular melanoma are also briefly outlined. Chapter 3 describes the patient popu-
lation included in this cohort study, summarises the relevant clinical demography
and identifies the outcomes of interest. These outcomes involve specific events, such
as local recurrence of the tumour or mortality, and the time between the treat-
ment and the occurrence of the events. Analysis of such information is complicated
because the observation time differs between patients and because not all events
were observed for all patients, so standard methods of examining the relation be-
tween variables are unsuitable. The appropriate statistical tools are identified and
explained. Chapter 3 also discusses the methods and materials used for other ob-
jectives of the study. The radiation doses deliverd to the tumour were re-calculated
for each patient using both a sophisticated and accurate protocol for calculating
dose distributions around radioactive sources, and the more simplistic calculation
protocol adopted in the COMS. The characteristics of the plaques and radiation
sources, the theoretical framework behind the dosimetry protocols and the software
program used to implement the protocols are described.
Chapter 4 outlines the commissioning of the software program and summarises
the doses calculated for the patient cohort, including a comparison of the doses
calculated under the two protocols. The treatment outcomes and the results of the
statistical modelling are presented in Chapter 5. The results in Chapters 4 and 5
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are compared with those from other trials and studies and are used as a basis for
the recommendations given in Chapter 6 for prescribing, planning and treating eye
plaques.
Chapter 2
Uveal melanoma: disease and
treatments
8
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2.1 Anatomy of the eye
A schema of the eye is shown in Figure 2.1. Tumours arise in the layers of tissue
covering the eye and so the structure of these three layers will be described in detail.
The fibrous outer layer comprises the clear cornea, covering the anterior surface, and
the opaque sclera. All blood vessels and nerves in the eye, including the optic nerve,
run through the sclera. The vascular, pigmentary middle layer is called the uvea
and comprises the choroid, ciliary processes, Ciliaris muscle and iris. The iris is a
thin, circular disk visible through the cornea, with a circular aperture of variable size
that allows light to enter the eye. The amount of light entering the eye is regulated
according to ambient conditions by contracting the iris. Vision is further adjusted
by lengthening and relaxing the lens to change its optical power. The Ciliaris muscle
is the main effector of changing the shape of the lens. The ciliary processes for a
ruff of layers of the choroid, which is a thin layer of tissue connecting the sclera and
retina, around the margin of the lens. Collectively, the ciliary processes and Ciliaris
muscle are known as the ciliary body.
The final layer, the retina, is a delicate nervous membrane. The retina is respon-
sible for detecting photons and converting these photons into a cascade of chemical
and electrical stimuli. The structure of the retina is complex as it must accommo-
date several layers of neurons interconnected by synapses. Photo-receptive neurons,
which are directly sensitive to light, are present in the inner layer of the retina
known as Jacob’s membrane. The two kinds of photoreceptors are the more nu-
merous rods, which are cylindrical cells arranged perpendicularly to the membrane
surface, and cones, which are conical cells positioned with the apexes directed to-
wards the choroid. Cone cells are less sensitive to photons than rod cells, but are
present in human eyes in three varieties. Each type of cone has a different response
curve to wavelengths of light, thus allowing humans to perceive colour.
The bulb of the eye appears as two fused segments of different sized spheres,
with the segment of the smaller sphere forming the anterior section of the eye.
The anterior segment contains two fluid-filled spaces; an anterior chamber lying
between the posterior surface of the cornea and the iris, and a posterior chamber
lying between the iris and the anterior surface of the vitreous body. Aqueous humour,
a clear fluid with a refractive index of 1.336, fills these spaces. The posterior segment
forms the posterior two-thirds of the eye and is filled with the vitreous humour.
The vitreous humour is a clear jelly-like substance, also with a refractive index of
around 1.336 but with a viscosity two to four times greater than that of water. The
transparency and high refractive index of the aqueous and vitreous humours allow
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light to be transmitted to through the pupil to the photo-receptive cells at the back
of the eye without refraction.
Figure 2.1: Anatomy of the human eye. Image reproduced from McGill University
website (http://thebrain.mcgill.ca).
2.2 Uveal melanoma
Melanomas originate in melanocytes, the melanin-producing cells found in the skin,
the uvea, the inner ear, meninges, bones and heart. Approximately 5% of all
melanomas arise in ocular and adnexal structures and around 80% of these melanomas
are uveal. The standardised incidence ratio in Australia is approximately 7.2 cases
per million person-years (standardised to the Australian 1991 population). The
disease can occur at any age but is usually identified in the fifth through seventh
decade. Host factors including race, genetic predisposition, sunlight exposure and
occupation have been investigated. Race appears to be the predominant risk factor;
incidence in fair-skinned people is around 150 times greater than in dark-skinned
people [5].
Iris melanomas are distinct from choroidal and ciliary body melanomas in cause
and development. Iris and cutaneous melanomas share aetological characteristics;
both often show mutations of the BRAF gene that are associated with damage from
UV radiation. However, iris melanomas are much more rare than other types of
uveal melanoma. No iris melanomas were prescribed radiation therapy at Royal
Perth Hospital during the period of investigation.
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Ciliary body and choroidal melanomas, often referred to collectively as posterior
uveal melanomas, usually appear as discrete, solid tumours. Choroidal melanomas
develop from the vascular eye wall and press the overlying retina into the vitreous
humour. The vitreous is avascular and so blood is supplied to the tumour through
the vessels in the basal uvea. Around three quarters of uveal melanomas develop a
domed shape, as illustrated in Figure 2.2. One quarter of tumours break through the
innermost layer of the choroid, Bruch’s membrane, to form ‘collar-button’ tumours,
as illustrated in Figure 2.3. Enucleated specimen have shown microscopic evidence of
invasion of the tumour into the sclera and emissary veins in around 50% of cases [6].
Ciliary body tumours are far more rare than choroidal melanomas, comprising only
around 10% of posterior uveal melanomas. The presence of ciliary body melanomas
is usually detected only when the tumour pathologically involves structures adjacent
to the ciliary body such as the lens or iris diaphragm, or disrupts the overlying ciliary
epithelium to interfere with production of aqueous humour.
The prognosis of choroidal and ciliary body melanomas is difficult to predict.
Late metastasis may occur after a long, disease-free interval and will almost always
involve the liver, which is the most common initial site of metastatic involvement
[5, 7]. The lung, bone and skin are also common sites for metastases, less so the
brain and adrenal glands. The mean survival time after diagnosis of metastatic
disease is ten months [7] and no effective treatment has been found for metastatic
choroidal and ciliary body melanomas [2, 8, 9].
Figure 2.2: A typical ‘dome-shaped’ choroidal melanoma that has not broken
through Bruch’s membrane. Figure reproduced from Finger [19].
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Figure 2.3: A ‘collar button’ choroidal melanoma. Figure reproduced from
Wikipedia (www.wikipedia.org).
2.2.1 Symptoms
Patients with uveal melanoma may present with complaints of visual loss, blurred
vision, flashing lights or ‘shadows’. However, all such symptoms are common to other
conditions of the eye and many melanomas do not cause any noticeable symptoms,
so choroidal or ciliary body melanomas may be discovered only during routine ocular
examination. Iris melanomas may be visible and so can be identified by the patient
from a change in iris colour.
2.2.2 Diagnosis
Diagnostic accuracy of uveal melanoma is greater than 99%. The melanoma may be
diagnosed from clinical observation via ophthalmoscopy, fundus photography and
ultrasound. A- and B-mode ultrasonography is now the gold standard for diagno-
sis of uveal melanoma, but the findings are usually characteristic of, rather than
specific for, melanoma. Uveal melanomas have low to moderate internal reflectivity
of ultrasound waves. A B-scan image of a uveal melanoma will typically show a
shadowy area posterior to the sclera behind the tumour. The shape of the tumour
can also be imaged from B-mode scans. A-mode scans, which display only density
differences at tissue interfaces along a single line, are useful for estimating the height
of the tumour. Fundus photography is used to evaluate growth of choroidal tumours
and response to therapy, and to check for recurrences. Fluorescein angiography is
used less frequently to provide supplementary information about tumour growth. It
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is performed by injecting fluorescein dye in to a vein in the arm and photographing
the dye as it circulates through the blood vessels in the uvea. ‘Double circulation’
patterns, characteristic of tumours that have broken through the inner layer of the
choroid, appear because dye circulating through retinal vessels will be superimposed
over dye circulating through abnormal vessels within the tumour. The retinal pig-
ment epithelium overlying choroidal tumours may also be altered and any small
leaks of fluorescein through the epithelium will appear as ‘hot spots’ on the pho-
tographs. CT and MR images may also be used but are less sensitive diagnostic
tools for ocular melanoma than other methods.
The differential diagnosis for uveal melanoma includes benign vascular lesions
and metastatic lesions such as adenocarcinomas of the breast, lung, bowel, kidney
or prostate [10, 11, 12]. Misdiagnosis of medium- and large-sized melanomas is
less than 1% [13] but diagnosis is less accurate for patients with smaller lesions
and for large tumours associated with substantial local haemorrage or large retinal
detachments.
2.3 Treatment options for uveal melanoma
Radiation therapy for ocular tumours was first introduced in 1929, but until the
1980s the routine approach to treatment of suspected ciliary body and choroidal
melanoma was enucleation. However, a reappraisal of the survival data on patients
with uveal melanomas who were treated by enucleation suggested adverse effects [3].
The authors of the study observed an abrupt rise in mortality rate following enucle-
ation, peaking 2 to 3 years after the procedure, which was considered incompatible
with the presumed natural history of uveal melanoma before enucleation. The rise
was attributed to release and dissemination of tumour emboli during enucleation.
The proposed explanation became known as the Zimmerman hypothesis and is still
contested; clinical, epidemiological, statistical and experimental evidence accumu-
lated since the publication suggests that the rise in mortality could be explained by
early metastasis of the melanoma [14]. Regardless of the validity of the Zimmerman
hypothesis, the publication provided further impetus to research and development
of alternative treatments for uveal melanomas.
2.3.1 Surgical options
Enucleation will eliminate all visible tumour and is associated with a high probabil-
ity of local control. If the tumour has extended into the orbit, orbital extenteration
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(removal of the entire eyeball, orbital soft tissues and some or all of the eyelids) and
postoperative external beam radiotherapy are usually employed. Lamellar, or full-
thickness eye-wall, resection is restricted mostly to lesions involving the iris or the
anterior ciliary body as concerns have been raised about residual disease following
lamellar resection [15]. Transpupillary thermotherapy, a form of laser photocoagu-
lation, has also been used with limited success for small choroidal melanomas and
for local control of tumours that have responded insufficiently to radiation therapy
[16].
2.3.2 External beam radiotherapy
External beam radiation therapy may be delivered using charged particles, such as
protons or helium ions, or by radiosurgery. Charged particle radiotherapy is usually
delivered with an anterior beam. Before treatment, radio-opaque markers such as
tantalum clips are sutured to the episclera around the base of the tumour to pro-
vide a means of localising the tumour using radiographic images. The patient is
asked to fixate on a non-moving target during treatment, which is typically deliv-
ered in daily fractions over five days. Typical doses are 10 to 16 Gy per fraction.
The clinical target volume usually includes the extent of the tumour as determined
from ophthalmic examinations (i.e., the gross tumour volume) surrounded by a 1
mm margin for sub-clinical disease. Further margins of 0.5 mm in the lateral and
craniocaudal dimensions and 2 mm margin in the posterior dimension are added to
allow for patient movement.
An anterior beam intended to irradiate a posterior uveal melanoma will enter
through radiosensitive structures such as the conjunctiva, cornea, iris, lens, vitreous
and the retina overlying the tumour. The average entry site dose from a beam of
charged particles is approximately 70% of the intended dose to the tumour [17, 18].
A literature review of radiation therapy for choroidal melanoma noted the relative
abundance of papers concerned with complications in the anterior segment of the
eye following charged particle radiotherapy [19]. The same review elucidated that
the severity, location and probability of radiation-induced complications are related
to the type of radiation used, the delivery method, the size of the tumour and the
dose delivered to normal ocular structures.
Stereotactic radiosurgery (SRS) for uveal melanomas was introduced in 1987
[20, 21, 22]. The technique allows precise delivery of a single large dose of radiation
to a small volume and excellent results for local control have been achieved. However,
there is a high risk of treatment complication as critical structures adjacent to the
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tumour will also receive large doses of radiation. The risk of complications may
be partly ameliorated by fractionating the dose. A typical fractionated treatment
would deliver around 10 Gy per fraction over 5 fractions and early results indicate
side effects are indeed reduced for fractionated stereotactic radiotherapy compared
with SRS [23].
External beam radiation therapy may be used as the primary means of treatment
or may be delivered before enucleation to sterilize malignant cells, or after enucle-
ation to treat residual tumour. Pre-operative radiotherapy does not improve survival
for large tumours [24] but typical doses delivered in pre-operative radiotherapy are
associated with significant complications in the normal extra-orbital tissue. Insuf-
ficient data are available on survival rates of patients who received post-operative
radiotherapy to show a statistically significant benefit of radiotherapy for residual
melanoma.
2.3.3 Eye plaque brachytherapy
Episcleral plaque brachytherapy has become the most widely available radiothera-
peutic treatment for ocular tumours. The earliest successful treatment of an ocular
tumour was performed in 1929 by Foster Moore, who inserted a radon seed into a
retinoblastoma through an incision in the sclera [25]. The treatment technique was
refined during the 1930s and 1940s, and by the 1960s Stallard reported the suc-
cessful treatment of 100 patients with circular and semi-circular plaques containing
Co-60 foil, sheathed in 0.5 mm platinum to absorb the 0.3 MeV β-rays. Treatment
with such high-energy photons was associated with severe side effects and concerns
about radiation safety, and so other radionuclides were investigated. Lommatzsch
pioneered the use of β-particles from Ru-106/Rh-106 and found, as expected, “the
severity and extension of post-radiation retinopathy is less than after Co-60” [26].
Plaques with removable photon-emitting sources in the form of seeds were later in-
troduced. Ir-192 and Pd-103 have both been used for eye plaques, but I-125, first
proposed as a suitable radioisotope for plaque brachytherapy by Packer and Rotman
[27], has become the most widely used.
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2.4 Review of major clinical trials and cohort stud-
ies of brachytherapy for uveal melanoma
A brief review of the results from some of the large clinical trials and cohort studies
of plaque brachytherapy for uveal melanoma will be presented here.
2.4.1 The Collaborative Ocular Melanoma Study (COMS)
The COMS randomised clinical trial of I-125 plaque brachytherapy versus enucle-
ation for treatment of choroidal melanoma accrued data over 11 and a half years
for 1317 patients. The trial intended to compare survival rates of radiotherapy with
enucleation for patients with medium-sized choroidal melanoma, as these patients
could feasibly be treated with plaque radiotherapy if the survival rate was found to
be comparable to that provided by enucleation. Strict eligibility and exclusion crite-
ria, outlined in the COMS Manual of Procedures and the COMS Form Book, were
applied. Standard episcleral plaques designed by the COMS Radiation Therapy
and Physics Committee, described in Section 3.2.3, were used at all participating
centres. Margins, prescription doses and dose rates, and dosimetry were all stan-
dardized. Briefly, for choroidal melanoma at least 5 mm in height the dose was
prescribed to the apex of the tumour. For tumours 2.5 to 4.9 mm in height, the
prescription point was 5 mm from the interior surface of the sclera. The dose to
the prescription point was 85 Gy, delivered at a rate of 0.42 to 1.05 Gy per hour.
The plaque size was selected to provide a 2- to 3-mm margin beyond the base of the
tumour.
A re-analysis of the doses delivered under the COMS protocol was performed by
Krintz et al. [28] using more sophisticated dosimetric data. The re-calculated doses
are discussed in Section 4.5.
2.4.1.1 Enucleation versus plaque brachytherapy
The estimated 5-year cumulative mortality rates (and 95% confidence intervals)
were 19% (16% - 23%) for patients in the enucleation arm and 18% (15% - 21%)
for patients in the brachytherapy arm [29]. Adjustment for time since enrollment
showed that mortality rates were nearly identical in the two treatment arms. The
risk ratio of 0.93 (95% confidence interval 0.76 - 1.14) in favour of brachytherapy is
equivalent to a 1.3% difference in mortality rate (bounds: +4.6% to -2.7%) in favour
of brachytherapy.
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A Cox proportional hazards survival model, in which treatment arm and base-
line characteristics of the tumour were included as covariates, indicated that the
following characteristics had independent and statistically significant effects on time
to mortality: age at time of enrollment, apical height of tumour, longest diameter of
tumour base, distance from the proximal tumour border to the optic disc, tumour
shape, smoking status, and coexisting medical conditions.
It should be noted that the COMS trial cannot and does not provide a definitive
answer to the original question of Zimmerman and colleagues, which asked whether
enucleation may change the natural history course of choroidal melanoma. Neither
arm of the COMS trial compared an intervention with natural history alone, and
such a trial would of course be considered unethical.
2.4.1.2 Local treatment failure
The risk of local treatment failure, defined by the COMS protocol as tumour growth,
recurrence or extrascleral extension as determined from echographic and photo-
graphic information [4], was examined for a subset of the COMS patient cohort.
The COMS also evaluated enucleation for reasons other than treatment failure,
such as ocular pain or neovascular glaucoma, in the context of brachytherapy failure
as, although enucleation for such reasons is not indicative of tumour recurrence, it
does represent failure of the secondary goal of plaque brachytherapy: preservation
of the globe [30].
A Kaplan-Meier estimate of the 5-year failure of local control was 10.3% (95%
confidence interval 8.0 - 13.2%). The 5-year cumulative risk of enucleation was
12.5% (95% confidence interval 10.0 - 15.6%). A Cox proportional hazards model of
local recurrence showed that factors associated with 5-year risk of local recurrence
included greater apical height, greater basal diameter of the tumour, retinal detach-
ment over the tumour and lower apical dose (p < 0.05 for all variables). Older age at
time of enrollment, poorer baseline visual acuity and location of the tumour relative
to the foveal avascular zone were weakly associated with greater probability of local
recurrence (p < 0.10 for all variables). The risk factors for enucleation, which were
evaluated separately, included male gender, greater apical height, greater basal di-
mension of the tumour, poorer initial visual acuity at baseline, collar-button shape
of the tumour, retinal detachment over the tumour, lower apical dose to the tumour
apex and higher dose to the sclera (p < 0.05 for all variables).
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2.4.1.3 Visual outcome
Visual outcome was examined for a subset of COMS patients. Under the COMS
protocol, an ophthalmic evaluation, including best-corrected visual acuity measure-
ment of both the treated and uninvolved eye, was performed baseline and then at
every six-monthly follow up examination [4] . Visual outcome of the treatment was
considered poor if the final visual acuity was 20/200 (equivalent to 6/60 in metric
units) or worse and / or if a loss of six or more lines Snellen visual acuity from base-
line was measured. At baseline, 10% of treated eyes had visual acuity of 20/200 or
worse; three years after treatment this percentage had risen to 45% [31]. A life-table
estimate of the percentage of patients who lost six or more Snellen lines of visual
acuity from baseline three years after treatment was 49%. The clinical factors most
strongly associated with poor visual outcome were greater baseline height of the
tumour apex, shorter distance between the tumour and the foveal avascular zone,
which is a region of the retina with a high concentration of cone photoreceptors, and
worse baseline visual acuity.
2.4.1.4 Recommendations
Following the release of preliminary results from the COMS trial, the American
Brachytherapy Society formed a panel to issue guidelines for the use of brachyther-
apy for choroidal melanomas [15]. The panel recommended that patients with small
T1 uveal melanomas (less than 2.5 mm in height and less than 10 mm in largest
basal dimension) should usually be observed for growth before treatment. Patients
with medium sized T2 uveal melanomas (2.5 to 10 mm in height and less than 16
mm in largest basal diameter) or large sized T3 or T4 melanomas (greater than 10
mm in height and / or greater than 16 mm basal diameter) require treatment if
the patient is otherwise healthy and free of metastatic disease. These patients are
candidates for plaque brachytherapy unless there is gross extrascleral involvement,
ring melanoma or the tumour involves more than half the ciliary body. Enucleation
is appropriate for patients with clinical diagnosis of uveal melanoma with one or
more of the following conditions; a painful blind eye, a tumour involving more than
40% of the intraocular volume, neovascular glaucoma, or if the patient has useful
vision in the uninvolved eye and does not wish to pursue an organ-sparing approach.
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2.4.2 Other cohort studies
2.4.2.1 Investigation of factors influencing visual outcome of treatment
Shields et al. investigated the clinical predictive factors for visual outcome in 1106
patients treated with plaque radiotherapy for uveal melanoma [32]. The retrospec-
tive cohort study considered only patients with initial visual acuity of 20/100 (equiv-
alent to 6/30 in metric units) or better in the affected eye. Post treatment, both
the final visual acuity and the loss of visual acuity were used to assess the visual
outcome of the treatment. The study found that 5 years after treatment one third of
patients had poor visual acuity, defined as visual acuity less than 20/200 (equivalent
to 6/60 in metric units). At 10 years of follow up, the proportion of patients with
poor visual acuity had doubled. The proportions of patients with moderate loss of
visual acuity, defined as loss of more than five lines Snellen visual acuity, at 5 and 10
years post treatment were also approximately one-third and two-thirds respectively.
Some of the clinical factors that best predicted poor visual acuity after treatment
were increasing tumour thickness, initial patient age of 60 years or older, tumour
recurrence, position of the tumour relative to the foveola and to the equator, sub-
retinal fluid and worse initial visual acuity. The use of cobalt-60 in the eye plaques
was also associated with poor visual acuity, although this factor should no longer be
of concern as cobalt-60 is now rarely used in episcleral eye plaques, mainly because
of safety concerns for the patient, carers and attending staff. The clinical factors
best predicting moderate loss of visual acuity included most of those factors best
predicting poor final visual acuity as well as diabetes mellitus and hypertension.
2.4.2.2 Eye plaque therapy in Western Australia
A retrospective review of eye plaque therapy in 49 patients with uveal melanoma
was performed by Sia et al. [33]. Kaplan-Meier estimates of 5-year disease-specific
survival and 5-year probability of local control were 92% and 80% respectively.
Treatment complications were also evaluated and local radiation retinopathy and
retinal detachment were found to be common, affecting 21% and 12% of patients
respectively. Poor visual outcome, defined as visual acuity of less than 6/60 after
treatment, was recorded for 18 of the 49 patients (37%).
The 49 patients included in the study by Sia et al. were included in the study
reported here, and the follow-up results recorded since the conclusion of the study
by Sia et al. have been added.
Chapter 3
Methods and Materials
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3.1 Sources
Radionuclides emitting low-energy photons, such as I-125 and Pd-103, are com-
monly used for brachytherapy procedures for a variety of anatomical sites including
choroidal melanoma. The dose gradients associated with low energy sources are ex-
tremely steep, therefore allowing some sparing of unaffected ocular structures, and
the radiation hazards to personnel and caregivers are usually manageable. Photon-
emitting sources for brachytherapy are usually encapsulated with titanium or steel.
The capsule is intended to contain the radioactive material, provide rigidity and, as
most isotopes used in brachytherapy are not pure photon emitters, to absorb any
unwanted α and / or β radiation. However, encapsulating the source in a mate-
rial with high atomic number has the usually undesirable consequence of producing
characteristic x-rays originating from the capsule.
The useful radiation fluence from I-125 sources consists of γ-rays and charac-
teristic x-rays emitted from electron capture or internal conversion in the iodine.
The mean energy of the emitted photons is 28.4 keV, but the photon fluence from a
brachytherapy source will be anisotropic and will be influenced by the source design.
3.1.1 The 6711 model
The Amersham® model 6711 source (now manufactured by Oncura®) was intro-
duced in 1983 and has become one of the most widely used, and therefore one of
the most widely studied, brachytherapy sources. A schema of the source is shown in
Figure 3.1. The source comprises a 4.5 mm long titanium capsule, with walls 0.05
mm thick and welded end caps, and a 3.0 mm long silver rod onto which I-125 is
adsorbed. Note that the thickness of the welded end caps is not specified, and that
the source may move within the titanium capsule. Monte Carlo investigations of
the dosimetric effects of source movement and thickness of weld ends have shown
that the dose rates along the transverse axis of the seed will not be significantly
influenced by such variations of the source geometry but the dose distribution and
energy spectrum around the capsule ends can vary dramatically [34, 35].
3.2 Eye plaques
Standard eye plaques are now available for purchase but custom-made plaques are
occasionally used at centres to optimize the dose distribution for irregularly shaped
tumours or for tumours located near the optic disc or ciliary body. This section will
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Figure 3.1: Schema of the Amersham 6711 source. Figure reproduced from Rivard
et al [41].
describe some of the eye plaque designs in which I-125 is commonly used and the
specific eye plaques considered in this study.
3.2.1 ROPES model
The Radiation Oncology Physics and Engineering Services (ROPES) model eye
plaques comprise an unrimmed stainless steel shell and an acrylic carrier. The
carrier contains slots into which the seeds are inserted. The centres of the seeds are
offset by approximately 1.1 mm from the inner surface of the carrier. A schema of
the ROPES eye plaque with a 15 mm diameter used in this study, which can be
loaded with up to 10 seeds, is shown in Figure 3.2. A more complete description of
the 15 mm ROPES eye plaque is provided in Granero et al [36].
3.2.2 In-house models
A series of eye plaques were created by the Technical Services Division of Medical
Engineering and Physics at Royal Perth Hospital. The eye plaques are similar in
design and construction to the ROPES models. The series comprises a rimmed eye
plaque with a 10 mm diameter that can be loaded with up to 4 seeds, an unrimmed
eye plaque with a 12 mm diameter that can be loaded with up to 7 seeds and an
unrimmed eye plaque with a 20 mm diameter that can be loaded with up to 17
seeds. The seeds in each carrier are offset by approximately 1.1 mm from the inner
surface of the carrier.
3.2.3 COMS models
The COMS provided a standardized set of plaques to be used only with I-125 sources.
The plaques comprise a Modulay (77% gold, 14% silver, 8% copper and 1% palla-
dium) shell with a cylindrical collimating rim, and a Silastic seed carrier into which
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Figure 3.2: Schematic image of the 15 mm ROPES eye plaque, including coordi-
nate system. Each seed slot is numbered. All lengths are in millimetres. Figure
reproduced from Granero et al [36].
the I-125 seeds are positioned [37, 38, 39]. The centre of each seed is offset approxi-
mately 1.4 mm from the inner surface of the carrier. It should be noted that Silastic,
made of Dow Corning medical grade elastomer MDX4-4210, is 40% silicon by weight
with an effective atomic number of approximately 10.7 and a density of 1.12 g/cm³
[38]. Silastic therefore cannot be considered water-equivalent, particularly because
the photoelectric interactions that are the dominant process for energy transfer at
low photon energies are highly dependent on atomic number. The standard COMS
plaques are available with diameters of 12, 14, 16, 18 and 20 mm.
3.3 Dosimetry for low-energy sources
The American Association of Physicists in Medicine (AAPM) Task Group No. 43
has published a protocol [40] based on the findings of the Interstitial Collaborative
Working Group (ICWG). The formalism for dose calculations introduced by Task
Group No. 43, updated in a later publication [41], will be referred to herein as the
TG-43 formalism.
A brief outline of the formalism for both 2D (cylindrically symmetric line source)
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and 1D (point source) dose calculations is presented below. The coordinate system
used for dosimetry calculations is shown in Figure 3.3.
Figure 3.3: The coordinate system used for dosimetry calculations. Figure repro-
duced from Rivard et al [41].
3.3.1 TG-43 Formalism
The two-dimensional dose-rate equation is given by:
D˙(r, θ) = SK · Λ · GL (r, θ)
GL (r0, θ0)
· gL(r) · F (r, θ) (3.1)
where r denotes the distance (in centimetres) from the centre of the active source
to the point of interest, r0 denotes the reference distance, specified to be 1 cm,
and θ denotes the polar angle specifying the point-of-interest, P (r, θ), relative to
the source longitudinal axis. The reference angle, θ0, defines the source transverse
plane, and is specified to be pi/2 radians, or 90°. The air-kerma strength, SK , is the
air kerma rate, K˙δ(d), in vacuo and due only to photons of energy greater than δ,
at distance d, multiplied by the square of this distance, d2,
SK = K˙δ(d)d
2. (3.2)
The energy cutoff, δ, is intended to exclude the contribution of low-energy or con-
taminant photons, such as the 4.5 keV characteristic x-rays emitted from the outer
layers of the titanium encapsulation, that will increase K˙δ(d) without delivering
significant dose to distances greater than 0.1 cm in tissue. For the purpose of eye
plaque dosimetry, the value of δ is usually 5 keV. The dose-rate constant, Λ, is the
ratio of the dose rate at the reference position, P (r0, θ0), and SK ,
Λ =
D˙ (r0, θ0)
SK
. (3.3)
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The dose-rate constant depends on both the radionuclide and source model as it is
influenced by the internal source design.
The geometry function, GL(r, θ), describes the relationship between dose rate
and increasing distance from the origin of the source geometry, neglecting scattering
and attenuation. The function is an effective inverse square-law correction using
an approximate model of the spatial distribution of radioactivity within the source.
The geometry functions for point- and line-source models recommended by TG-43
are:
GP (r, θ) = r−2 (point-source approximation),
GL(r, θ) =

β
Lr sin θ if θ != 0◦,
(r2 − L2/4)−1 if θ = 0◦
(line-source approximation),
where β is the angle, in radians, subtended by the tips of the hypothetical line
source with respect to the calculation point, P (r, θ), and L is the active length of
the source.
The radial dose function, gX(r), accounts for the effects of photon scattering and
attenuation on the transverse plane of the source. It is defined as
gX(r) =
D˙ (r, θ0)
D˙ (r0, θ0)
GX (r0, θ0)
GX (r, θ0)
. (3.4)
The radial dose function is equal to unity at r0 (1 cm). The 2D anisotropy function,
F (r, θ), describes the variation of dose rate as a function of the polar angle relative
to the transverse plane of the source. It is defined as
F (r, θ) =
D˙ (r, θ)
D˙ (r, θ0)
GL (r, θ0)
GL (r, θ)
. (3.5)
While F (r, θ) is defined as unity along the transverse plane of the source, at points
off the transverse plane the function typically decreases as r decreases, as θ ap-
proaches 0° or 180°, as encapsulation thickness increases and / or as the photon
energy decreases.
The data provided in TG 43 (and later updates) for the dose rate constant,
active length, radial dose function and anisotropy function for specific source models
are based on peer-reviewed publications of experimental measurements and Monte
Carlo simulations. Results for the 6711 source model from Monte Carlo simulations
using cross-section libraries other than those equivalent to the current NIST XCOM
database were excluded, as were those attempting to simulate the Loftus free-air
chamber air kerma standard strength rather than the NIST 1999 standard.
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3.3.2 COMS formalism calculations
For the purpose of comparison with published clinical trials, the dosimetry used
for the Collective Ocular Melanoma Study (COMS) will briefly be presented here.
COMS dosimetry can be considered a simplified form of the TG-43 formalism. The
formalism assumes a point source and applies a radial dose function to account for
scattering and attenuation with distance from the source. The effects of source
anisotropy, side attenuation and backscatter from the gold shield, and attenuation
by the Silastic insert are all ignored. The one-dimensional isotropic point-source
approximation recommended under the COMS protocol is given by:
D˙(r) = SK · Λ · GX (r, θ0)
GX (r0, θ0)
· gX(r), (3.6)
where SK and Λ are defined as above. The geometry function and the radial dose
function were the point-source approximations described above.
Doses were calculated for all treatments using both the COMS and line-source
formalisms. However, the doses calculated with the COMS formalism are presented
only to illustrate the systematic errors introduced by using the simplified calcu-
lations. All analyses of patient outcome included only the more accurate doses
calculated with the line-source formalism.
3.3.3 Radiobiological doses
The radiobiological doses to the sclera and tumour apex were calculated using
the linear-quadratic (LQ) equations described in Dale [42, 43] for low dose-rate
brachytherapy. The biologically effective dose (BED), which depends on both the
dosimetric parameters and the radiobiological properties of the tissue, indicates the
amount of lethal damage inflicted on a specific tissue. The BED for a continuous
brachytherapy treatment delivered at a low dose rate R over time T is given by:
BED = RT
[
1 +
2R
µ (α/β)
(
1− 1
µT
(
1− e−µT ))] . (3.7)
The (α/β) ratio indicates the sensitivity of the tissue to the dose rate. The parame-
ters α and β represent the linear and quadratic components of radiation sensitivity
in the linear-quadratic equation of cell survival. The mono-exponential recovery
constant µ is related to the half-life T1/2 for repair of sublethal damage by
µ =
ln 2
T1/2
.
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In this study it was assumed that the (α/β) ratio for the both the apex and sclera
was 10 Gy and that T1/2 was 1.5 hours. Both values are typical of cancerous tissue,
although it has been argued that the radiobiology of melanomas is very different
to that of other cancerous tissue and so the (α/β) ratio would likely be different.
Further, the radiobiological dose is not linearly proportional to the dose and so if
the dose to a volume is highly non-uniform, which is certainly the case for any
brachytherapy treatment, the radiobiological dose cannot be calculated from the
average dose to that volume. The apical dose can possibly be considered uniform
in the case of dome-shaped tumours, but the scleral dose will vary by orders of
magnitude. The radiobiological doses calculated here for the sclera should therefore
be viewed as relative rather than absolute quantities. However, relative doses are
sufficient for the purpose of this study as published values of radiobiological doses
for clinical trials of eye plaque patients are not available.
3.4 Plaque Simulator
The Plaque Simulator program (227 BEBIG GmbH, Berlin, Germany) was devel-
oped at the University of Southern California [37]. The program is intended for use
for dosimetry of ophthalmic plaques. The plaques may be categorised as plaques
with long-lived isotopes (Co-60 and Ru-106) and plaques intended for use with sealed
radioisotopes that are temporarily inserted (Ir-192, Pd-103 or I-125). The program
has libraries of models of commonly-used source and plaque models but also allows
the user to create new models of plaques and / or sources, or modify existing ones.
3.4.1 Coordinate system and geometry
The origin of the coordinate system of the plaque is the centre of the sphere to
which the plaque conforms. The plaque coordinate system is shown in Figure 3.4. If
a scaled model of the plaque’s structure is available, the precise slot coordinates can
be derived. The position and orientation of a seed slot are uniquely identified by
three angles that describe the displacement from a standard position and orientation.
With reference to Figures 3.4 and 3.5, the standard position is defined as x =
− (plaqueRadius + seedOffset) , y = 0, z = 0. The standard orientation is defined
as the long axis of the slot parallel to the z-axis (seedTilt = 0°). The slot is first
rotated about the x-axis by the angle specified by seedTilt, then rotated about the
y-axis by angle seed α and finally rotated about the x-axis again by angle seed β.
The plaque description must also include the thickness of the plaque on central axis
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(caxHeight), the dimensions and positions of the suture eyelets and a table of radii
which approximate the perimeter of the metal shell. A plaque file may be created
by entering these parameters from the plaque model information or by digitising the
plaque outline and slots from photographs.
Figure 3.4: The Plaque Simulator coordinate system. Figure reproduced from As-
trahan et al [37].
Figure 3.5: Lateral view of the Plaque Simulator coordinate system. Figure repro-
duced from Astrahan et al [37].
The location of the tumour and ocular dimensions such as the diameter of the
lens, limbus and equator, and the anterior-posterior pole length, may be specified
by the user from information acquired from CT, MRI and / or ultrasound images.
The user may specify the position of the plaque on the eye. No imaging information
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for the patient cohort used in this study was available. It was assumed that the
plaque was centred over the tumour, but the dosimetric consequences of a 1 mm
plaque misplacement were considered. The results are included in 4.7.
3.4.2 Dose calculation algorithm and corrections
The algorithm used for dosimetry calculations for eye plaques is based on superpo-
sition of doses and therefore does not account for any shielding of the fluence from
one source by another source. However, Monte Carlo studies of I-125 seeds have
shown that the variation of dose rate due to absorption and scatter from neighbour-
ing seeds is negligible for seeds aligned along the longitudinal axis, except at points
θ < 10◦[44]. As such points would be contained within the acrylic insert, it can be
assumed that the effects of inter-source shielding are not important for eye plaque
dosimetry.
Dose calculation matrices ranging from 20 × 20 points to 160 × 160 points are
applied to a planar dosimetry surface of side length 2 mm to 40 mm. Isodose contours
between calculation points are estimated via bi-linear interpolation. Alternatively,
the dose at a point on the dosimetry surface can be explicitly calculated. The
dosimetry algorithm initially considers each seed as either a point or a line source,
as specified by the user, in a full scatter geometry. The user also specifies which, if
any, dose modifying factors are applied. These factors are discussed below.
3.4.2.1 Scatter modifier factor
The scatter modifier factor accounts for inhomogeneity of the scatter geometry and
is specifically applicable to gold plaques. The scatter modifier factor was therefore
not applied for dose calculations for any of the plaques used in this study.
3.4.2.2 Carrier factor
The carrier factor is intended to correct for attenuation of primary photons in the
source carrier. The factor should be implemented if the carrier is significantly non-
water equivalent. As the density and atomic composition of Perspex is approxi-
mately equivalent to that of water, the carrier factor was not applied for any of the
dose calculations for this study.
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3.4.2.3 Shell collimation
The shell collimation algorithm accounts for attenuation of the primary radiation
passing through the shell of the plaque. Secondary scatter effects are ignored. It
is assumed that the direct photon fluence from each source is collimated by the
lip of the plaque; any backscatter is ignored as measurements have shown that
backscatter due to the plaque contributes around 3% of the unshielded dose rate
[45]. However, it should be noted that the algorithm underestimates dose in the
penumbral region of the plaque. The effects of shell collimation were incorporated
only for dose calculations that used the line-source formalism.
3.4.2.4 Air interface factor
The anterior surface of the eye is surrounded by air. Very few photons emitted into
the air will scatter back into the eye. The reduction of dose as a function of distance
from the air interface (assuming a posterior placement of the plaque, as appropriate
for treatment of a choroidal or ciliary body melanoma) can be accounted for with a
factor
A(R) = 0.85 + (0.1×R) (3.8)
where R is the distance from the air interface (in centimetres). The equation, de-
termined empirically from measured data [39], is valid for R ≤ 1.5 cm. In Plaque
Simulator the air gap is modelled as a plane through the cornea and tangential to
the anterior oblate spheroid of the eye model on the anterior-posterior axis of the
eye. An air interface factor was applied only to dose calculations that used the
line-source formalism, with the assumption of a posterior placement of all plaques.
3.5 Patient population
A total of 138 patients treated for uveal melanoma with an episcleral eye plaque
at Royal Perth Hospital were treated between 1985 and 2006. However, complete
patient records and dosimetric information were available for only 114 patients.
Five patients were lost to follow-up and the physics data necessary to re-calculate
doses was incomplete for another 19 patients. The remaining 114 patients were
included in the retrospective study. A database was created to record the patient
name and hospital ID, patient age at treatment, treatment date, gender, information
about visual acuity before and after treatment, details about the tumour dimensions,
treatment parameters (plaque size, source loading pattern, source activities at start
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of treatment, actual treatment time), and information about treatment outcome.
Of the 114 patients included in the study, 52 (46%) were female and 62 (54%) were
male. The average age of the patients was 59 (range: 28 - 86).
3.5.1 Patient work-up
The patient work-up included a general physical exam as well as liver function stud-
ies (LFTs), computer tomography (CT) imaging and chest x-rays to assess for hep-
atomegaly and subcutaneous nodules. An ophthalmologic examination, including
intraocular pressure and a measure of (best corrected) visual acuity, was performed.
If available in the patient records, the visual acuity of both the diseased and unin-
volved eye was recorded.
3.5.1.1 Visual acuity scoring system
Visual acuity was accorded a score of 1 to 4, using the following classifications:
1: Visual acuity 6/9 or better,
2: Visual acuity 6/12 to 6/36,
3: Visual acuity 6/36 to less than 6/60, or
4: Visual acuity 6/60 or worse.
A summary of the visual acuities recorded before treatment is shown in Table 3.1.
Details of the visual acuity of the uninvolved eye were missing for 15 patients. One
uninvolved eye was a prosthesis and scored as having a visual acuity of 4.
Visual acuity score Diseased eye Uninvolved eye
1 53 84
2 30 10
3 5 1
4 26 4
Table 3.1: Summary of patients by visual acuity score of diseased eye and uninvolved
eye before eye plaque therapy.
3.5.1.2 Tumour staging
The apical height and maximum basal diameter of the tumour were recorded in
the patient database. The TMN tumour classification for ciliary body and choroid
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uveal melanoma, based on thickness and basal diameter, used by the American Joint
Committee on Cancer has been employed here. The tumour size classifications are:
T1: tumours not greater than 3.0 mm in height and with a largest basal
diameter not greater than 12.0 mm or between 3.1 mm and 6.0 mm in
height and with a largest basal diameter not greater than 9.0 mm.
T2: tumours not greater than 3.0 mm in height and with a largest basal
diameter between 12.1 mm and 18.0 mm or between 3.1 mm and 6.0
mm in height and with a largest basal diameter between 9.1 mm and
15.0 mm or between 6.1 mm and 9.0 mm in height and with a largest
basal diameter not greater than 12.0 mm.
T3: tumours between 3.1 mm and 6.0 mm in height and with a largest basal
diameter between 15.1 mm and 18.0 mm or between 6.1 mm and 12.0
mm in height and with a largest basal diameter between 12.1 mm and
18.0 mm or between 9.1 mm and 15.0 mm in height and with a largest
basal diameter not greater than 15.0 mm.
T4: all tumours with a basal diameter greater than 18.0 mm or greater than
15.0 mm in height or between 12.0 mmand 15.0 mm in height with a
basal diameter between 15.1 mm and 18.0 mm.
Note that subcategories exist for each size according to the involvement of the ciliary
body and the presence and size of extraocular extension. No nodal involvement
nor metastases were detected before treatment for any of the patients treated with
episcleral plaque therapy. A summary of the tumour stages recorded for the patient
cohort is shown in Table 3.2.
Tumour stage Number of patients
1 34
2 62
3 18
4 -
Table 3.2: Summary of patients by tumour stage before eye plaque therapy.
The COMS classifies tumours as small, medium or large. The linear measure-
ments of the apical height and maximum basal dimension of the tumour were used
to classify it as small (1 mm to 2.5 mm in apical height, < 5 mm in maximum
basal dimension), medium (> 2.5 mm to 10 mm in apical height and ≤ 16 mm in
maximum basal dimension), or large (≥ 2 mm in apical height and > 16 mm in
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maximum basal diameter or > 10 mm in apical height) [4]. Under the COMS classi-
fication system, all but one ‘large’ tumour in this patient cohort would be classified
as ‘medium’.
3.5.2 Patient follow-up
Follow-up of patients included semi-annual assessment of visual acuity in both the
treated and untreated eye, and a dilated eye examination of the treated eye. Patients
were also required to have annual LFTs.
3.5.2.1 Endpoints
Details of detected recurrence of the tumour, time to recurrence, detected metas-
tases, time to detection of metastases, time to mortality, enucleation of the treated
eye and time to enucleation were recorded in the patient database. If available in
the patient records, the visual acuity in both eyes five years after treatment was
recorded. Recurrence was defined as failure of the tumour to reduce in size, as de-
termined from ophthalmologic examination. Distant metastatic disease was defined
from the results of an imaging study that demonstrated cancer outside the orbit.
Following the methodology of Shields et al. [32], visual acuity was analysed for
two end points; final visual acuity and loss of visual acuity. Visual acuity of better
than 6/60 at final follow-up date was classed as ‘good’, visual acuity of 6/60 or worse
was classed as ‘poor’. Loss of less than 5 Snellen lines between the start of treatment
and final follow-up was classed as ‘good’, loss of five or more Snellen lines was classed
as ‘poor’. If either end point was classed as poor, the overall visual outcome of the
treatment was also classed as poor. Patients who underwent enucleation were also
classed as having a poor visual outcome.
3.6 Statistical methods
Survival analysis is the study of the time from an intervention to an event of interest
(such as recurrence or mortality). Clearly, there are at least two variables of interest
here; whether or not an event occurs, and the time to the event. However, the
event of interest is almost never observed in all subjects. The majority of patients
included in this study were still alive at the end of the study period and so the
survival time for these patients is unknown, other than that it is longer than the
period of observation. Such survival times are referred to as censored, meaning
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that observation was stopped before the event of interest occurred. Further, the
observation periods differ between patients, so the length of the observation period
must also be considered. Survival analysis must therefore account for censoring and
the length of observation. In this section a brief review of the relevant statistical
tools will be presented. Although the following section will focus on survival, another
event of interest such as local recurrence may also be investigated using the same
methodology.
From our data we wish to estimate the proportion of patients receiving eye plaque
therapy expected to survive a given length of time, but analysis of the risk presented
by ocular melanoma is further complicated by the competing risk of death from
unrelated causes; over half of the mortalities observed in this study were ascribed to
natural causes. The standard method of analysing the survival times is the Kaplan-
Meier (KM) method, which is both easy to understand and to use, but in the case
of competing risks KM estimates of survival will be biased. Bias is introduced if the
risks are dependent, which is likely the case here as the risk of dying of unrelated
causes and of metastatic melanoma both increase with age at time of treatment
[29]. Moreover, the KM method also ignores censorship of the event of interest
from the competing risk; a patient who dies of natural causes is not at risk of
dying from metastatic melanoma. The standard test for comparing survival rates
between groups of patients receiving different treatment, the log-rank test, is also
inappropriate as the test is performed by comparing curves generated with the KM
method and, as the competing risks for the groups may differ, is therefore subject to
the same sources of bias. Finally, the standard model used to examine the factors
that will influence survival, the Cox proportional hazards model, will also be biased
by the competing risks.
Note that Kim [46] provides an excellent, far more detailed, discussion of survival
analysis of competing risks data.
3.6.1 The survival function, the cumulative incidence func-
tion and the hazard function: a general overview
The two fundamental functions of interest in survival analysis are the survival func-
tion and the hazard function. The survival function S(t) gives the probability of
surviving to time t, and the complementary cumulative incidence function then gives
the probability of mortality to time t. The hazard function represents the risk of
dying in a very short time interval after time t, given survival until that time.
The survival probability at a certain time t is clearly a conditional probability;
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it is conditional on survival just before to that time. Similarly, the cumulative inci-
dence of mortality can be estimated as the probability of dying at time t given sur-
vival until that time. The survival time t following an intervention may be thought
of as a random variable, with a distribution function represented as a probability
density function f(t) and a cumulative distribution function F (t) = Pr(T ≤ t). The
survival function S(t) is defined in Equation 3.9 as the complement of the cumulative
distribution function:
S(t) = Pr(T > t) = 1− F (t). (3.9)
The hazard function h (t) indicates the instantaneous probability of dying just after
time t given survival until that time:
h(t) =
lim
∆t→ 0
Pr [(t ≤ T < t+∆t) | T ≥ t]
∆t
=
f(t)
S(t)
. (3.10)
Clearly, the hazard function is also a conditional probability as the risk of mor-
tality usually changes over time. The hazard function can be interpreted as the
number of events, such as mortalities, expected to occur per individual per unit of
time. It is also a conditional probability; the risk of an event occurring is unlikely
to be constant over time. However, it is often difficult to model either the hazard
function or the probability density function f (t), so survival analysis often relies on
non-parametric, empirical means of studying both the survival and hazard functions.
The standard method of estimating survival probability uses the KM estimate,
which is defined as the product of the conditional probabilities until that time. The
KM estimate gives the empirical probablity of survival and is non-parametric, so
no assumptions about the hazard function are required. In mathematical notation,
if ni is the number of patients alive at time ti and di is the number of mortalities
observed at time ti then the conditional probability of surviving past time ti, given
survival until that time, is estimated as pi = (ni − di)/ni. The KM estimate is
the unconditional probability of surviving past any time t and is given by Equation
3.11:
SKM(t) =
∏
t(i)≤t
pi. (3.11)
The cumulative incidence calculating using the KM estimator, CIKM (t) is there-
fore simply:
CIKM (t) = 1−
∏
t(i)≤t
pi = 1− SKM (t) . (3.12)
To compare the survival rates of two or more groups of patients, the observed and
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expected numbers of mortalities in discrete time intervals should be calculated and
summed. The null hypothesis, that the survival rates are not significantly different,
can be accepted or rejected using the log-rank test. The log-rank test statistic, χ2,
can be calculated as:
χ2 =
(O1 − E1)2
E1
+
(O2 − E2)2
E2
(3.13)
where O1 and O2 are the summed observed number of mortalities for the first and
second groups respectively, and E1 and E2 are the summed expected number of
mortalities for the first and second groups respectively. A more accurate estimate of
χ2 is obtained from the variance of the difference between the observed and expected
number of mortalities per time interval for each group. The log-rank test statistic
may then be calculated via Equation 3.14 as
χ2 =
(O1 − E1)2
V
(3.14)
where V is the sum of the variances. The test statistic χ2 is then compared to a
standard χ2 distribution with 1 degree of freedom to obtain a probability that the
two curves are different.
Often, rather than absolute survival, the relationship between survival and sev-
eral covariates, such as the age of the patient at the time of treatment or the height
of the tumour, is of interest. The hazard function may be modelled as a function
of these covariates, usually assuming a linear-like model of the log hazard. For ex-
ample, a parametric regression model assuming an exponential distribution of the
hazard rate would be expressed as
log hi(t) = α + βxi (3.15)
where the xi is the vector of covariates for patient i, β is a vector of regression coef-
ficients and the constant α represents a log-baseline hazard. The Cox proportional
hazards model [47] is semi-parametric as the baseline hazard function is unspecified,
so
log hi(t) = α (t) + βxi (3.16)
The covariates are incorporated into the model through the linear predictor
ηi = βxi (3.17)
which does not contain a constant term. The Cox regression model is a model
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for proportional hazards as any change in a covariate xi will have the effect of
multiplying the hazard rate by a constant value. This property is demonstrated by
considering the linear predictors for two patients i and i′. The predictor for patient
i is given above and the predictor for patient i′ is given by:
ηi′ = βxi′ . (3.18)
The hazard ratio for these two observations is
hi(t)
hi′(t)
=
h0(t)eni
h0(t)eni′
=
eni
eni′
, (3.19)
and it is easy to see that the hazard ratios will differ by a factor proportionate to
the differences of the covariates. The great strength of the Cox model is that, if
that the coefficients of the covariates are known (or estimated), it is possible to
predict the relative hazard for a specific patient and, if treatment-related covariates
are included in the model, it will be possible to reduce the hazard by optimising the
treatment parameters.
3.6.2 Incorporating competing risks into survival models
Competing risks may be incorporated into the theoretical framework of survival
analysis by considering the joint distributions of the time to mortality t and the
cause of mortality. The cause-specific hazard function then becomes:
hj(t) =
lim
∆t→ 0
Pr [(t ≤ T < t+∆t, cause = k) | T ≥ t]
∆t
=
f(t)
S(t)
, k=1, 2 ... K.
(3.20)
The cause-specific hazard for a cause j is the instantaneous mortality rate from this
cause in the presence of all other possible causes of mortality. However, a model of
the hazard function would require assumptions about the dependency between the
competing risks, and such assumptions would be untestable. The survival function
can instead be modelled empirically, but modifications are required.
3.6.2.1 Cumulative incidence of mortality in the presence of competing
risks
Many studies have estimated the cumulative incidence of an mortality in the case
of competing risks as simply the complement of the disease-specific KM estimator.
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This method treats failures from competing causes as censored observations. Using
this methodology, the cumulative incidence of disease-specific mortality, CIdsKM , is
calculated as:
CIdsKM (t0) = 1− SdsKM (t0) = 0 (3.21)
(i.e., all patients are alive at the start of the study),
CIdsKM (ti) = 1− SdsKM (ti) = CIdsKM (ti−1) + SdsKM (ti−1)×
(
ddsi
ni
)
where SdsKM (ti−1) denotes the KM estimate of survival probability for disease-specific
mortality at time ti−1, ddsi denotes the number of disease-specific mortalities observed
at time ti and ni denotes the number of patients at risk of all causes of mortality
just before time ti.
The method used to analyse survival in the presence of competing risks (CR)
requires only a small modification; it estimates the probability of survival just prior
to a certain time by considering the probability of both disease-specific mortality
and of mortality due to unrelated causes. Mathematically, the cumulative incidence
of disease-specific mortality in the presence of competing risks, denoted as CIdsCR, is
calculated as:
CIdsCR (t0) = 0 (3.22)
CIdsCR (ti) = CI
ds
KM (ti−1) + S
all
KM (ti−1)×
(
ddsi
ni
)
where SallKM (ti−1) denotes the KM estimate of probability of surviving for all causes
of mortality at time ti−1 and the other variables are as defined above. Using this
method, patients dying from unrelated causes are included in the calculation of sur-
vival at time t and only patients who are alive, rather than only those who have
not died from the disease, are considered at risk of mortality. The KM method uses
the estimate SdsKM (t), which is always greater than or equal to SallKM (t) in the CR
method, so the estimated cumulative incidence of disease-specific mortality calcu-
lated with the KM method is always overestimated. Magnitudes of overestimation
will depend on the incidence rates of the competing risks.
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3.6.2.2 Comparing CI curves in the presence of competing risks: the
Gray test
The standard log-rank test used to compare cumulative incidence curves is not
appropriate because the test compares the number of mortalities at each time ti
without accounting for different causes of mortality. Gray [48] proposed a class of
tests that may instead be used for comparison of survival curves for a particular
cause of mortality in the presence of competing risks. The test modifies the log-
rank test statistic by including a weighting factor for the expected number of events
at each time ti for each group. The weighting factor for group 1 is calculated as the
ratio (
R1i
R1i +R2i
)
(3.23)
where
R1i = n1i
(
1−D1 (ti−1)
S1 (ti−1)
)
(3.24)
and D1 (ti−1) and S1 (ti−1) are the respective probabilities of disease-specific mortal-
ity and mortality from any cause at time ti for group 1.
3.6.2.3 Modifying the Cox regression model
Several approaches have been proposed for estimating the influence of covariates
in cases where competing risks are involved. The method proposed by Lunn and
McNeil [49] assumes that the hazard functions from the competing risks are additive,
so the hazard of mortality is the sum of all risk processes, and the time to mortality
is the minimum of the times associated with the different risks. However, when the
observation period for an individual ends, due to either mortality or because the
study has finished, multiple survival times of equal length are observed, one for each
category of risk, all of which but one will be censored.
The Lunn and McNeil method models the hazard from two competing risks to
fit two vectors of regression coefficients β0 and β1 (the method can be extended to
consider multiple competing risks). The method is implemented by duplicating the
data for each subject, including a category to specify the cause of mortality δi where
δi assumes the values 0 and 1. The original entry should not be modified; the second
entry should be altered so that the cause of mortality is now (1− δi) but the event
status θi is always censored. An example for patient i who died at time t is shown
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in Table 3.3. If the entry for a patient is censored, the entry is again duplicated but
now both entries show a censored observation. The covariates xi are augmented to
allow for possible interactions between the covariates and the cause of mortality δi.
The modified model may be fitted as a model stratified by cause of mortality, or
as a model including cause of mortality as a covariate. The second method of fitting
the model is more efficient but less robust. As only two causes of mortality are
considered here fitting the model is quick and so the stratified method was adopted.
Patient time to mortality Event status θi Cause Covariates
i (original) t 1 δi xi, δixi
i (duplicate) t 0 (1− δi) xi, (1− δi)xi
Table 3.3: Example entry for patient i who died of cause δi. Event status θi: 0 =
censored, 1 = mortality.
3.7 Model diagnostics for the Cox proportional haz-
ards model
It is essential to determine if a fitted Cox regression model adequately describes the
data. The following concerns should be examined before accepting the model: vio-
lation of the assumption of proportional hazards, influential data, and nonlinearity
in the relationship between the log hazard and the covariates. If the tests indicate
the model is found inadequate, it may be possible to change the way the data is
included in the model by, for example, including a time variation for the coefficients.
The standard methods for testing goodness of fit for ordinary models of multiple
regression cannot be applied to the Cox model as some survival times are censored.
It is also not possible to calculate and examine residuals between the data and
model in the usual way. Instead, tests and graphical diagnostics may be based on
the scaled Schoenfeld residuals arising from the initial fit [50]. Schoenfeld residuals
are calculated as separate residuals for each individual for each covariate k as
residual = xik −
j∈R(ti)∑
i=1
xjkwj (3.25)
where xik is the value of the covariate x for the individual i who died at time ti, wj
is a weighting factor that represents each individual’s likelihood of dying at time ti,
and R (ti) represents the risk set; all patients who are at risk of mortality at time
ti. Clearly, the risk set excludes patients who are censored at time ti and patients
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who have already died at ti,. The sum thus represents the expected value of the
covariate for the risk set at time ti calculated as a weighted average of the covariate.
The influence of individual observations is assessed by examining the change dfβ
in the value of the regression coefficient β calculated for each covariate k when each
observed value xik is deleted in turn. The values of dfβ for each covariate of interest
should be displayed on an index plot. If a few outliers dramatically influence the
estimated coefficient, it is expected that the changes will be of similar magnitude to
the coefficient. Highly influential observations do not per se invalidate the model
but the robustness of the model may be questioned.
The assumption of linearity between each covariate and the log hazard must
also be tested. A straightforward means of verifying the assumption is by plotting
the smoothed martingale residuals against covariates. This approach assumes that
covariates are not correlated, which is a valid assumption for these data as correlation
coefficients between age, apical dose rate and apical BED were all not significant.
The martingale residual for subject i at time ti is given by
Mi = θi − Hˆ0 (ti) exp
j∈R(ti)∑
i=1
βkxkj
 (3.26)
where Hˆ0 (ti) is the cumulative baseline hazard function (which can be estimated
from the model), βk is the nominal coefficient for covariate k, and θi is the event
status, which is assigned a value of 0 if ti is a censored time and a value of 1 if
the individual has died at ti. The martingale residual therefore represents, at each
time t, the difference over the period [0, t] in the number of observed events and the
number predicted by the model. A plot of the martingale residuals for a specified
covariate often shows two distinct distributions of the residuals clustered according
to the value of the event status θi.
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4.1 Commissioning of the Plaque Simulator treat-
ment planning system
The tasks required for commissioning of a treatment planning system (TPS) are
described in Chapter 9 of the Technical Reports Series No. 430 (TRS-430) [51].
Some of the general tests for radiation therapy treatment planning system, including
image display and plan evaluation tools, are relevant for this specific TPS. There
are some concerns specific to commissioning of a TPS for brachytherapy, including
the description of dose calculation algorithms and of the source configuration. The
commissioning process described here is limited to the use of model 6711 I-125
OncoSeeds in the ROPES eye plaque of 15 mm diameter. The reference data for
the sources and the formalism for manual calculations of dose were obtained from
recommendations of Task Group 43 Update 1 (TG-43U1) [41]. The test numbering
system used in TRS-430 was adopted here.
The criteria for acceptability of the accuracy of the dosimetry calculations were
based on the recommendations of Van Dyk et al [52]. However, the tolerance for tests
of source strength decay and treatment time were limited to the error introduced
from rounding of values as the relevant parameters (half-life and elapsed time) and
correction factors (based on exponential decay of source strength) are well-defined.
4.1.1 Commissioning Tests
4.1.1.1 Anatomy test 12: Defining points, lines and marks
The location of the tumour can be adjusted by either clicking and dragging the
tumour to the appropriate position on the 2D model of the eye or by specifying the
tumour co-ordinates in the Standard Tumour Dialog window. The display of the
tumour position on the eye was verified by comparing the two methods of locating
the tumour.
4.1.1.2 Anatomy test 14: Two dimensional image tools
The correct functioning of the display tools was verified using an eye model based
on a two dimensional CT image. The rotation, zoom, windowing and grey-scale
display functions were tested.
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4.1.1.3 Anatomy test 18: Measurement tools
The capabilities and accuracy of measurement tools, including the ruler, and polar
grid were verified using the eye model generated with the CT image. Measurements
were performed in different directions and with the display zoomed. Any changes
to the co-ordinate systems were noted.
4.1.1.4 Dose Test 1: Source description, parametrisation and reference
data
All coefficients and basic data entered in the Plaque Simulator TPS are consistent
with the characteristics and dosimetric properties of the 6711 I-125 Oncoseed sources
as used for clinical planning. The quantity and units used to describe the source
strength, physical characteristics of the source, units for dose, dose rate and distance,
definition of geometry relative to the source and any underlying assumptions used
in the calculations were examined and were considered appropriate for treatment
planning of eye plaques.
4.1.1.5 Manual calculations
The dose distribution at several points between 2.5 mm and 20 mm along the central
axis from a single I-125 source were calculated manually using the two-dimensional
formalism given in TG-43U1. The TPS dose calculations were compared with values
calculated using the following equation:
D(r) = SK .Λ.
GL (r, θ0)
GL (r0, θ0)
.gL(r).F (r, θ),
where the value of Λ, the dose rate constant in water, is 0.965 cGy.h−1.U−1 for the
6711 model seeds. For this test, F (r, θ) was assumed to be 1.00 for all points along
the central axis. Values of the radial dose function were taken from Table II in
TG-43U1 and non-tabulated values were determined by logarithmic interpolation.
The source strength was specified as 1.27 cGy.cm2.h−1, corresponding to a source
activity of 1.0 mCi. The implant time was specified as 1 hour so the dose was not
corrected for decay of the source during treatment.
The tolerance for the agreement between the manual calculations and the dose
calculations obtained from Plaque Simulator was 5%.
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4.1.1.6 Brachytherapy Dose Test 2: Dose distribution from a single
source
The doses at points at polar angles other than 90° to the source transverse plane were
also calculated using the general two-dimensional formalism described in TG-43U1.
Values of the radial dose function and anisotropy function were respectively taken
from Tables II and V in TG-43U1. Non-tabulated values of the radial dose function
and anisotropy function were calculated via logarithmic and linear interpolation re-
spectively. The source strength was specified as 1.27 cGy.cm2.h−1. The tolerance for
the agreement between the manual calculations and the dose calculations obtained
from Plaque Simulator was 5%.
4.1.1.7 Brachytherapy dose test 4: Correction for source strength decay
before application
Plaque Simulator makes use of a source inventory and so correction for any decay of
source strength prior to the application must be tested. For this test, the dose was
calculated at a point 10 mm from the centre of the source. The reference strength
and reference date were noted. The dose was then recalculated at the same point but
with the start date (a) one half-life and (b) two half-lives later than the reference
date. The tolerance for the agreement between the manual calculations and the
calculations obtained from Plaque Simulator was 0.3% (attributable to rounding
errors).
4.1.1.8 Brachytherapy dose test 5: Computation of treatment time
The Plaque Simulator TPS is capable of computing the treatment time for eye
plaques and so the validity of the algorithm for computation of application time
must be checked. The dose distribution computed in Dose Test 2 was used as the
prescription and the resulting manual calculation of time was compared with the
Plaque Simulator computation. The purpose of this test is to check the validity of
the algorithm for computation of the treatment time. The tolerance for the agree-
ment between the manual calculations and the calculations obtained from Plaque
Simulator was 0.2% (attributable to rounding errors).
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4.1.1.9 Brachytherapy dose test 6: Correction for source strength decay
during application
The radionuclide of interest (I-125) has a relatively short half-life of 59.4 days. The
correction applied to the treatment time to account for source decay during the
application was tested by computing the dose at a point 10 mm from the centre of
the source for two different application times, each expressed as a fraction of the
radionuclide half-life. The tolerance for the agreement between the manual calcula-
tions and the calculations obtained from Plaque Simulator was 0.3% (attributable
to rounding errors).
4.1.1.10 Brachytherapy dose issue 1: Dose distribution around the source
arrangement (and applicators)
Calculation of the contribution from several sources must be accounted for. The mu-
tual influence of the sources is generally ignored and not tested. The recommended
procedure for verifying the calculation of the contribution from multiple sources in
TRS 430 is to duplicate the source used in Dose Test 2 and check that the dose is
doubled. However, Plaque Simulator restricts the positioning of sources and so the
calculation of the dose distribution from multiple sources was tested by creating the
15 mm diameter ROPES eye plaque in Plaque Simulator and loading each of the
ten slots with a 1.0 mCi source. The radius of the inner ring of three seeds was
2.755 mm and the radius of the outer ring of seven seeds was 5.947 mm. The inner
ring of seeds was 0.814 mm above the centre of the inner surface of the plaque (the
origin of the coordinate system) and the outer ring was 0.312 mm below the center
of the plaque inner surface. The dose distribution at points along the central axis
of the plaque was calculated. The implant time was specified as 1 hour so the dose
was not corrected for decay of the source during treatment. The dose distribution
from each source was calculated as for Dose Test 1.
The tolerance for the agreement between the manual calculations and the dose
calculations obtained from Plaque Simulator was 5%.
4.1.1.11 Brachytherapy dose issue 2: Changing options and editing of
source characteristics
The dose distribution must be updated when dose calculation options and / or
source characteristics are modified and the plan identification must be modified
accordingly. The configuration used in Dose Issue 1 was used and the following
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options were changed:
• Position of the reference point,
• Treatment time,
• Number of sources, and
• Source strength.
The plan identification printed onto the summary sheets was checked to ensure that
the association between the list of selected options was unambiguous.
4.1.1.12 Dose display test 2: isodose lines and surfaces
There are four options for display of isodoses in Plaque Simulator; all lines and
tints disabled, lines enabled, lines and tints enabled, and lines and tints and labels
enabled. The tumour model and prescription available in the Basic Tutorial file in
Plaque Simulator was used. The dose at the tumour apex was compared between the
available views of the eye model and between the available isodose display options.
4.1.1.13 Dose-volume histogram test 1: Types of dose-volume histogram
Only cumulative dose volume histograms (DVHs) are available in Plaque Simulator.
The capability of the system to create DVHs was tested using the Basic Tutorial
patient file and hard copy outputs of the DVHs were compared with the displayed
DVHs to check consistency.
4.1.2 Results
4.1.2.1 Anatomy test 12: Defining points, lines and marks
It was confirmed that both methods of positioning the tumour (manually entering
co-ordinates versus dragging and dropping) result in identical tumour locations.
Further, it is also possible to manually enter the parameters of the model of the eye,
including:
• anterior-posterior axis,
• lateral diameter,
• eccentricity,
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• limbus diameter,
• lens centre,
• lens diameter,
• lens width, and
• disc angle.
These parameters can be adjusted in the ‘Eye size’ dialog window. All options
also appear functional, and the changes to the eye model were consistent with the
changes to the parameters.
4.1.2.2 Anatomy test 14: Two dimensional image tools
The rotation and zoom options appeared functional and correct. The model may
be rotated by adjusting the entered x -, y- and z -axis rotations or by clicking and
dragging on the model. The window and grey-level adjustments for the CT image
were functional and the option to invert grey levels is included. The window and
grey levels can be easily adjusted by dragging the window over the displayed grey
level histogram.
Further, there are options to adjust the opacity of the sclera, retina, lens, cornea,
tumour, plaque, radioactive sources and isodose curves. The tumour can be dis-
played as translucent, opaque or with edges only shown, and may be indicated on
the model as a peak, a dome or a customised icon.
4.1.2.3 Anatomy test 18: Measurement tools
The accuracy of the ruler was verified using the model of the eye created from the
calibrated CT image. The measurements obtained with the ruler were consistent
with the dimensions of the eye as determined from the model of the CT image. A
polar grid is also available on the ‘Retinal diagram’ window. The grid also appears
accurate to within 1 mm. Both tools functioned correctly when the magnification
of the image was increased.
4.1.2.4 Dose test 1: Source description, parametrisation and reference
data
The results of dose test 1 for the 6711 model OncoSeeds are given in Table 4.1.2.4.
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The source strength may be specified in the Plaque Simulator inventory in terms
of either the Air Kerma Rate or the apparent activity of the source. The conver-
sion factor relating the Air Kerma Rate of I-125 sources to the apparent activity
is consistent with the value given in TG-43U1. Although Air Kerma Rate is the
parameter of source strength recommended for brachytherapy by the American As-
sociation of Physicists in Medicine [40], the sources supplied by Oncura are specified
by the apparent activity of the sources. The dimensions of the silver source marker,
the outer titanium capsule and the active length of the source entered in Plaque
Simulator are also consistent with the source geometry data given in TG-43U1.
The values of the dose rate constant used by Plaque Simulator is consistent with
value given in TG-43U1. Both one- and two-dimensional calculations of dosimetry,
based on the formalism given in TG-43U1, are possible but it is recommended that
two-dimensional calculations should be used.
Units for dose can be toggled between cGy and Gy. The units for distance are
given in millimetres. It was noted that the version of Plaque Simulator used for this
study expresses dates according to European convention (dd/mm/yyyy).
The origin of the Plaque Simulator coordinate system is at the centre of a sphere
defined by the radius of curvature of the inner surface of the plaque. The z -axis of
the coordinate system is also the central axis of the plaque. However, user points
are entered according to a coordinate system with an origin at the centre of the eye
(assumed to have a radius of curvature of 12 mm).
4.1.2.5 Dose Test 2: Dose distribution from a single source
The distance between the centre of a seed positioned in a slot along the central
axis of the plaque is 1.1 mm. The origin of the coordinate system used in Plaque
Simulator is the inner surface of the plaque and so 1.1 mm is subtracted from the
central axis positions in Plaque Simulator.
4.1.2.6 Central axis depth dose data
The manual calculations of central axis dose agree with the Plaque Simulator values
to within 1.0%. The discrepancy between the calculations may be attributed to the
values of radial dose function used in Plaque Simulator. The program uses a 2001
element extended lookup table covering the range of zero to 40 mm at increments of
0.02 mm. The table was calculated from fifth order polynomial coefficients, whereas
the values used for the manual calculations were obtained directly from TG-43U1
or were interpolated logarithmically. The central axis calculations are therefore
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considered acceptable.
4.1.2.7 Off-axis depth dose data
The manual calculations of the off-axis dose distributions agree with the Plaque Sim-
ulator values to within 5%. The discrepancies are most likely attributable to differ-
ences in the radial dose function (as discussed in Section 4.1.2.6) and the anisotropy
function. Plaque Simulator uses a 91-element extended anisotropy lookup table
covering the ranges of 0◦ to 90◦ at increments of one degree. The lookup table is
interpolated from up to 20 data pairs. Note that according to TRS 430: “If the
TPS algorithm is based on an average anisotropy correction, discrepancies larger
than 5% can be found, especially along the source axis. Such local discrepancies are
generally acceptable.” [51]
4.1.2.8 Dose test 4: Correction for source strength decay before appli-
cation
The manual calculations of the dose at a point 10.0 mm from the centre of the seed
(i.e. 8.9 mm along the central axis of the plaque) agree with the Plaque Simulator
values to within 0.3%.
4.1.2.9 Dose test 5: Computation of treatment time
Plaque Simulator calculated the time required to deliver 1.216 Gy to a point 8.9
mm along the central axis of the plaque (7.9 mm from the inner sclera) as 1.000
hours. The manual calculation of treatment time therefore agrees with the Plaque
Simulator calculation to within 0.0%.
4.1.2.10 Dose test 6: Correction for source strength decay during ap-
plication
The dose at a point 8.9 mm along the central axis of the plaque was calculated
for the treatment times given in Table 4.1.2.10. All Plaque Simulator calculations
agreed with the manual calculations to within 0.0%.
4.1.2.11 Issue 1: Dose distribution around the source arrangement (and
applicators)
The manual calculations of the central axis dose distribution for the 15 mm ROPES
plaque loaded with ten 1.0 mCi seeds agreed with the Plaque Simulator calculations
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t1(hours) t2(hours) D1 (cGy) D2 (cGy) D1/D2
142.6 71.32 167.5 85.2 1.97
285.3 142.6 323.9 167.5 1.93
713.2 142.6 732.9 167.5 4.37
2853 1426 1876 1251 1.50
Table 4.2: Treatment times and corresponding doses
to within 0.5%.
4.1.2.12 Issue 2: Changing options and editing of source characteristics
New summary sheets were printed after each change to the source and treatment
options. All doses and treatment times were updated correctly in Plaque Simulator
and the time stamp printed on the summary sheet was changed to reflect the update.
If details in the seed inventory were changed the user was alerted to the change and
asked if they wished to continue using the seeds from the altered inventory.
4.1.2.13 Dose display test 2: isodose lines and surfaces
The display of the dose to the apex of the tumour was consistent between the
‘Retinal diagram’ display and the ‘Dosimetry’ display and between the three options
for isodose display. It should be noted that if the magnification of the ‘Dosimetry’
window is changed it is necessary to recalculate the dose distribution. However,
calculation times are of the order of seconds.
4.1.2.14 Dose-volume histogram test 1: Types of dose-volume histogram
Cumulative DVHs indicated that 100% of the tumour volume received the prescribed
dose, as expected. Doses to the tumour and eye were consistent between hard and
soft copies. Note that the DVH doses can be adjusted by double clicking on the
DVH document and entering a fixed dose range.
4.1.3 Conclusions
The dose calculation algorithms used in Plaque Simulator are acceptably accurate.
The program dosimetry algorithms are based on the TG-43U1 formalism and the
final calculations appear for both single sources and clinically relevant source con-
figurations are consistent with manual calculations using the TG-43U1 formalism
and parameters. Plaque Simulator accurately accounts for source decay prior to and
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during treatment and alerts the user to any changes to the seed inventory. Image
import and display and the display of doses is accurate.
4.2 Comparison of central axis dose rates with COMS
and line-source formalism
The 10 mm, 12 mm and 20 mm diameter plaques used at RPH for this cohort study
were modelled in the Plaque Simulator TPS according to the method described
in the Plaque Simulator User Manual. A model of the 15 mm ROPES plaque is
supplied as standard with Plaque Simulator. The dose rates along the central axis
of the plaques calculated with the line-source formalism are consistently lower than
those calculated under the COMS formalism. The difference between dose rates
is between 1.9% and 2.4% for each plaque and increases with central axis distance
from the surface of the plaque, approaching an upper limit of 3.7% for all plaques.
It is therefore expected that the doses, and dose rates, to the sclera calculated with
the line-source formalism will be consistently around 2% lower than those calculated
under the COMS formalism, but the difference between apical doses, and dose rates,
will vary with the height of the apex. Dose rates calculated with both formalisms as a
function of distance along the central axis, and differences expressed as a percentage
of the COMS dose rate, are shown in Figures A.1, A.2, A.3 and A.4 in the Appendix.
4.3 Dosimetry calculations
Treatment margins were measured, using the on-screen measuring tool in Plaque
Simulator, as the linear distance from the point where the isodose line covering the
apex of the tumour intersects the surface of the inner sclera to the basal edge of the
tumour.
4.3.1 COMS formalism
The median values (± standard deviations) of the apical and scleral doses and dose
rates, as calculated using the COMS formalism, are shown in Table 4.3.
4.3.2 Line-source formalism
The median values (± standard deviations) of the apical and scleral doses and dose
rates, as calculated using the line-source formalism, are shown in Table 4.4.
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Total dose(Gy) Dose rate(cGy/h) Margin (mm)
Apex Sclera Apex Sclera
64.7 (± 5.2) 267 (± 95) 59 (± 18) 240 (± 87) 2.9 (± 1.5)
Table 4.3: Mean values (± standard deviations) of apical and scleral doses and dose
rates, and margin of 100% isodose line, as calculated using the COMS formalism.
Total dose(Gy) Dose rate(cGy/h) Margin (mm)
Apex Sclera Apex Sclera
62.5 (± 5.4) 260 (± 91) 57 (± 17) 234 (± 85) 2.8 (± 1.5)
Table 4.4: Mean values (± standard deviations) of apical and scleral doses and dose
rates, as calculated using the line-source formalism.
4.3.3 Radiobiological doses
The median values (± standard deviations) of the BEDs to the apex and sclera, as
calculated using the COMS and the line-source formalism, are shown in Table 4.5.
BED to apex (Gy) BED to sclera (Gy)
COMS Line-source COMS Line-source
82 (± 9) 78 (± 9) 570 (± 290) 550 (± 280)
Table 4.5: Mean values (± standard deviations) of apical and scleral BEDs, as
calculated using the COMS and the line-source formalisms.
4.3.4 Comparison of line-source and COMS formalism doses
The margin was defined by the distance between the maximum basal diameter of the
tumour and diameter of the volume encompassed by the isodose covering the tumour
apex. A positive value indicates that this isodose surface covers the tumour base. All
but two treatments had positive margins as calculated using either dose formalism.
The margins measured from distributions calculated with the line-source formalism
were systematically larger than those measured from the point-source distributions
(Student’s t-test p-value < 0.01). The apical and scleral doses were significantly
higher when calculated with the point-source model (all p-values < 0.05) than the
line-source model.
The coefficients of variation of doses and dose rates to the apex and sclera for both
the point-source and line-source models are shown in Table 4.6. Unsurprisingly, the
inter-patient variations of the apical doses are small relative to the observed inter-
patient variations of scleral doses. The ratio of scleral to apical dose will depend
on the thickness of the tumour. The coefficient of variation of tumour thicknesses
is 30% and so the variability of tumour thickness contributes the majority of the
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inter-patient variability of scleral dose. The treatment time also varies considerably
between patients (coefficient of variation of 28%) and therefore, although the to-
tal dose to the apex is reasonably consistent between patients, large inter-patient
variation is observed for apical dose rates. The variation of total dose to the sclera
and of treatment time both contribute to the variation of scleral dose rate between
patients.
Apex Sclera
Dose Dose rate Dose Dose rate
Point Line Point Line Point Line Point Line
8.0 8.6 31 30 36 34 36 36
Table 4.6: Percentage coefficients of variation for apical and scleral doses and dose
rates, as calculated with the point-source (Point) and line-source (Line) formalisms.
4.4 Uncertainties
The sources of uncertainties associated with dosimetry of eye plaque treatments arise
from uncertainty of the tumour dimensions, precision of placement of the plaque over
the tumour, treatment planning errors, source-related uncertainties and error in the
treatment time.
1. Diagnostic errors arise because of inaccuracies in the ultrasound measurements
of tumour height and diameter. Image pixel size and caliper precision, im-
age resolution, distance calibration and uncertainty in ultrasound propagation
due to variation in tissue density all contribute to the uncertainty of linear
ultrasound measurements. The estimated uncertainty (1 standard deviation)
arising from all these sources is 1 mm [53].
2. Treatment errors will be introduced from inaccuracy of placement of the plaque
over the base of the tumour and because elapsed time between diagnosis and
treatment will allow growth of the tumour over this period. Tumour growth,
although likely to be small, will introduce systematic underestimation of the
height of the tumour. The sclera is assumed to be 1 mm thick over the surface
of the eye for the purpose of dosimetry calculations, but the sclera varies in
thickness not only between patients but also over the surface of the eye. The
mean scleral thickness (± 1 standard deviation) at the limbal area of the eye
is 0.53 ± 0.14 mm, whereas near the equator the mean scleral thickness (±
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1 standard deviation) is 0.39 ± 0.17 mm [54]. The overestimation of scleral
thickness may partially ameliorate the systematic underestimation of tumour
height. The precision of positioning the plaque is assumed to be approximately
1 mm, and the net uncertainty of the height of the tumour due to treatment
errors is assumed to be -0.5 mm.
3. Variations between TG-43 calculations and Plaque Simulator calculations are
discussed in Section 4.1.2. Note that TG-43 parameters and dose calculations
also introduce error as the TG-43 formalism, whilst sophisticated, still provides
only an approximation of the true dose distribution around radioactive sources.
4. Source-related uncertainties include the difference in nominal and actual air-
kerma rates of sources. It is recommended that the difference between the
mean air-kerma rate of a batch of sources be within 3% of the stated air-kerma
strength, and that the maximum deviation from the mean for an individual
source should be less than 5% [55]. For the purpose of this study, a deviation
of each individual seed from the stated air-kerma strength was assumed, so the
average error (1 standard deviation) in the overall air-kerma strength of each
fully loaded plaque is estimated as 2.5% (10 mm plaque), 1.9% (12 mm plaque),
1.6% (15 mm plaque) and 1.2% (20 mm plaque). The difference between the
manufacturer’s calibration time (unknown) and the use time, and the time
difference of 14 hours between the place of use (Perth, Western Australia)
and the place of calibration (Illinois, United States of America), introduces
a small systematic error of e−14×λ = 0.7%. Finally, inter-source variations of
source geometry, such as variation of the dimensions of the titanium capsule
[34] will lead to further differences between planned and delivered doses; such
variations have not been included here.
5. Temporal uncertainty (insertion and removal times) will likely be small and
so the error in treatment time is estimated as 10 minutes (0.16 hours).
The sources of uncertainty and their estimated magnitudes are summarised in Table
4.7. The percentage error each source of uncertainty would contribute to the dose
to the apex delivered from a typical eye plaque treatment for a tumour of median
height (5.6 mm) and median diameter (10.2 mm), treated with a 15 mm eye plaque
for the median treatment time of 118 hours, is also estimated. The uncertainty
associated with measurement of the basal diameter would not affect the apical dose
but would affect the treatment margin and the dose to nearby structures at risk.
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Tumour height Error Percentage error
Tumour height ± 1.1 mm -15 % / +24 %
Plaque positioning ± 1.0 mm -5 %
Scleral thickness -0.5 mm +7%
TG-43 / Plaque Simulator ± 2% ± 2 %
Calibration time 14 hours ± 0.7 %
Source variation ± 5% (per source) ± 1.6%
Treatment time ± 0.2 h ± 0.2 %
Combined uncertainty -15 / +26 %
Table 4.7: Sources of uncertainty for eye plaque dosimetry.
4.5 Comparison of dosimetry with the COMS trial
doses
The doses reported in the COMS literature should not be compared directly with
those reported here as the effects of the Silastic carrier and, to a lesser extent, the
gold backing and the source geometry, are not accounted for in the COMS dosimetry.
The radiation doses delivered to the tumour apex and other structures of interest
within the eye were recalculated for patients on the COMS trial using updated
dosimetric data [28] and it was found that doses to all structures were reduced by
7% to 21%, depending on plaque size and structure. The median reduction of dose
to the tumour apex was 11% and so the prescription dose and recommended range
of dose rates were 75.7 Gy and 0.37 Gy/h to 0.93 Gy/h respectively, rather than the
values of 85 Gy and 0.42 Gy/h to 1.05 Gy/h calculated under the COMS formalism.
The median dose delivered to the tumour apex in this study is 62.5 Gy as calcu-
lated using the line-source formalism, which is around 17% lower than the nominal
apical dose of 75.7 Gy delivered under the COMS as calculated using the same for-
malism. Similarly, the dose rates to the tumour apex delivered in this study were
not within the range prescribed under the COMS for all patients. Three of the
patients (3%) received apical dose rates calculated with the line-source formalism
greater than 0.97 Gy/h and 11 patients received apical dose rates less than 0.37
Gy/h (10%).
Margins were defined in the COMS according to the plaque diameter relative to
the maximum basal diameter of the tumour. A summary of the treatment margins
as defined by the COMS for the RPH cohort is presented in Table 4.8. If the
COMS criterion of 2 mm for the treatment margin was applied, the margins of
only 18 of the 114 treatments would be considered adequate. However, the COMS
definition ignores the relationship between the dose distribution at the sclera and
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the tumour height; for any plaque size, the area of the sclera covered by a given
isodose will increase with increasing height of the prescription point (and therefore
with apical height). For this reason, the margins incorporated into the statistical
models discussed in Chapter 5 are based on the position of the 100% isodose relative
to the tumour base.
Margin (mm) Number of patients
< 0 2
1 < margin ≤ 0 37
2 < margin ≤ 1 57
3 < margin ≤ 2 18
Table 4.8: Summary of the treatment margins calculated using the COMS definition:
(plaque diameter - maximum basal diameter of the tumour)/2.
Chapter 5
Assessments of treatment outcome
59
5 Assessments of treatment outcome 60
Note that all treatment parameters (doses, dose rates and biologically effective
doses) discussed in this Chapter are calculated using the line-source formalism unless
stated otherwise.
5.1 Initial fitting and testing of the models
5.1.1 Cox proportional hazards models
5.1.1.1 Competing risks survival
An initial Cox proportional hazards model was fitted to the data relating survival
times to the following variables: age at treatment, tumour height and maximum
basal dimension, enucleation following treatment, the dose, dose rate and BED at
the tumour apex and at the sclera, and the minimum margin between the 100%
isodose line and the tumour base. The model indicated that the age, apical dose
rate and apical BED covariates all showed statistically significant effects on the
length of survival (p < 0.05). The scleral BED showed a borderline significant
influence on the length of survival (p = 0.059).
The scaled Schoenfeld residuals for the subset of covariates with significant co-
efficients were plotted as a function of (transformed) time and the correlation co-
efficients were determined. A new Cox model was created to include only age,
apical dose rate and apical BED as covariates. The correlation coefficients between
the Schoenfeld residuals and time for the three covariates were all not statistically
significant (p > 0.05), indicating that the assumption of proportional hazards is
reasonable. Plots of the scaled Schoenfeld residuals against transformed time for
each covariate are shown in Figure B.1 in the Appendix. The plots support the
assumption of proportional hazards as the smoothing spline fit to each plot does not
show any systematic trend over time.
The influence of individual observations was investigated using the plots of dfβ,
shown in Figure B.2 in the Appendix, for age, apical dose rate and apical BED.
Almost all values of dfβ were several orders of magnitude smaller than the corre-
sponding coefficients, with a single obvious outlier in the apical dose rate data. This
datum corresponded to the treatment for the smallest tumour in the dataset (apical
height of 2.0 mm) and the shortest treatment time (48.2 hours). The treatment
data were checked and were found to be correct but highly atypical of eye plaque
treatments. The value of dfβ for this treatment is 0.019, approximately one order of
magnitude smaller than the coefficient for the apical dose rate and, as it appears to
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be the only highly atypical datum, it was concluded that the model was adequately
robust.
Plots of the martingale residuals for each of the three covariates, as well as plots
of the residuals plus the component values of the covariates, are shown in Figure B.3
in the Appendix. The plots indicate that any nonlinearity between each covariate
and the log hazard is slight. It was therefore decided to accept the Cox model for
disease-specific survival.
The above process was repeated for Cox models of tumour recurrence and visual
outcome.
5.1.1.2 Local recurrence
The initial model for local recurrence indicated that the coefficients for age, enucle-
ation of the treated eye, and scleral dose, were statistically significant. The model
parameters are displayed in Table 5.1. Enucleation is associated with a five-fold in-
crease in probability of tumour recurrence per month. Obviously, correlation must
not be confused with causality; almost 60% of enucleations were performed because
of local recurrence or tumour growth after treatment. An examination of the Schoen-
feld residuals of the model showed strong evidence of non-proportional hazards for
enucleation (p = 0.014), but the assumption of proportional hazards for age and
scleral dose appeared reasonable (p > 0.05 for both tests).
Coefficient (β) eβ SE(β) z p
Age 0.027 1.027 0.013 2.132 0.033
Enucleation 1.67 5.33 0.35 4.753 2×10−6
Scleral dose -0.027 0.974 0.009 -3.039 0.0023
Table 5.1: Estimated model parameters for initial Cox model (only parameters for
covariates with statistically significant coefficients are shown).
Plots of dfβ for the coefficients for age, enucleation and scleral dose (shown in
Figure B.5 of the Appendix) were examined. The (absolute) largest values of dfβ
were at least one order of magnitude smaller than the coefficients and so it was
concluded that the coefficients were not unduly influenced by outlying observations.
The martingale residuals were calculated and plotted against the age and scleral
dose covariates (nonlinearity is not a concern for enucleation as this covariate is
dichotomous). No obvious non-linearity in the plots shown in Figure B.6 in the
Appendix was evident. It was decided to exclude enucleation as a covariate as
enucleation is usually an outcome of, rather than a predictor for, local recurrence
and because the covariate violates the assumption of proportional hazards. The
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new Cox model showed a statistically significant coefficient only for the scleral dose
and the Schoenfeld residuals for the new model indicated that the assumption of a
proportional hazard for scleral dose is reasonable.
5.1.1.3 Visual outcome
An initial Cox model included patient age, tumour height, maximum diameter,
treatment margin, apical dose, dose rate and BED, and scleral dose, dose rate and
BED as covariables. Enucleation was excluded as a covariate as it was used to classify
treatment outcome and as enucleation was often performed because a patient had
poor visual outcome after treatment. The initial model indicated that none of the
coefficients for the covariates was statistically significant. The Schoenfeld residuals
showed no evidence of non-proportional hazards for any of the covariates.
5.1.2 Cumulative incidence models
The R software package ‘cmprsk’ was used to implement the Cumulative Incidence
models.
5.1.2.1 Competing risks survival
The cumulative incidence function of mortality due to metastatic melanoma was
modelled by treating mortality due to unrelated causes as a competing risk. The
Cox model estimated significant coefficients for the treatment variables apical dose
rate and apical BED, so the effects of these variables on the cumulative incidence of
mortality were examined separately by classing the value of the treatment variable
received by a patient as either high (greater than the modal value) or low (less
than the modal value) and calculating the subdistribution functions for the different
patient groups. The dose rate and BED groupings are shown in Table 5.2.
Apical dose rate (cGy/h) Apical BED (Gy)
< 51.6 > 51.6 < 76.5 >76.5
Median 46.1 66.3 72.1 82.1
No. patients 58 56 56 58
Table 5.2: Patient groups according to apical dose rate and apical BED.
5.1.2.2 Local recurrence
The cumulative incidence function of local recurrence was modelled by treating
mortality due to unrelated causes as a competing risk, although it could be argued
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that if enucleation were considered as an endpoint, enucleation due to unrelated
causes could also be regarded as a competing risk. However, only ten enucleations
(9% of treatments) were performed for reasons other than tumour recurrence so the
competing risk of non-specific enucleations was ignored.
The final Cox model estimated a significant coefficient only for the scleral dose co-
variate. The scleral dose received by each patient was classed as either high (greater
than the modal value) or low (less than the modal value), and the subdistribution
functions for cumulative incidence of local recurrence were calculated for the two
groups. The scleral dose groupings are shown in Table 5.3.
Scleral dose (Gy)
< 250 > 250
Median 194 309
No. patients 58 56
Table 5.3: Patient groups according to scleral dose.
5.1.2.3 Visual outcome
Death from any cause can be regarded as a competing risk for poor visual outcome of
a treatment, as it can be assumed that death from an unrelated cause will preclude
poor visual outcome, and recurrence (and subsequent metastasis) of a tumour will be
associated with increased risk of enucleation and therefore of poor visual outcome.
5.2 Survival outcomes
As of the analysis date, 36 patients (32%) were known to have died, 17 (15%)
from metastatic melanoma and 19 (17%) from unrelated causes. The estimated 5-
year cumulative mortality rate (and 95% confidence intervals) determined from this
study is 12% (6% - 17%), which is consistent with the 5-year rate of mortality of
9% for patients receiving eye plaque brachytherapy under the COMS trial [29]. The
cumulative incidence of mortality from metastatic melanoma, as predicted using the
competing-risks model, is shown in Figure 5.1.
The 5-year cumulative mortality rates for the patients grouped according to
apical dose rate and to apical BED, as well as the median value of each treatment
variable for the group, are shown in Table 5.4. Figures illustrating the cumulative
mortality functions for high and low apical dose rates and high and low apical BEDs
are shown in Figure B.7 and B.8 respectively in the Appendix. Patients receiving a
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Figure 5.1: Cumulative incidence of mortality, as estimated using the competitive-
risks model.
low apical BED are twice as likely to die within five years as those receiving a high
apical BED, and a Gray test confirmed that the cumulative incidence of mortality is
significantly greater for the patients receiving a low apical BED than a high apical
BED (p < 0.01). It is clear from both the tabulated data and the figure that there
is little difference in the estimated cumulative incidence of mortality between the
apical dose rate groups, as confirmed by a Gray test.
Apical dose rate Apical BED
High Low High Low
Median value 74.2 39.5 86.4 68.6
5-year Cumulative mortality (%) 12 13 8 17
Table 5.4: Cumulative 5-year mortality rates for treatment groups. Apical dose
rates are expressed in cGy/h and apical BEDs are expressed in Gy.
The parameters for significant covariates estimated from the accepted Cox model
of survival are shown in Table 5.5. It should be noted that the parameters of the
competing risks model are not significantly different from the parameters obtained
if an unstratified, disease-specific model is fitted. The results are consistent with
those of the COMS, which indicated that age at time of enrollment (and presumably
at time of treatment) had a significant effect on length of survival, although the
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coefficient is not quoted. Treatment factors including apical dose rate and apical
BED were much more consistent between treatments in COMS and were therefore
either not considered as covariates in the Cox model or the estimated coefficients
were not statistically significant. Unlike the COMS results, the covariates for the
baseline characteristics of the tumour did not show statistically significant effects
on the length of survival.
The Cox model for this study predicts a positive coefficient for patient age,
indicating that if all other covariates are held constant, increasing age at the time of
treatment increases the monthly risk of mortality by, on average eβ = 1.06 (by 6%
per month) per year increase in age. The coefficient estimated by the Cox model for
the apical BED was consistent with the results from the cumulative incidence model.
The model predicts that increasing the apical BED reduces the monthly mortality
risk by eβ = 0.72 (by 28% per month). The coefficient for the apical dose rate is
positive, indicating that an increase of the apical dose rate by 1 cGy/h corresponds
to an increase of eβ = 1.16 (by 16% per month). Note that, as the Cox model
assumes that the proportionality of hazards is independent of time, these results are
not dependent on time t.
The cumulative incidence model suggests that increasing the apical dose rate
by from 68.6 cGy/h to 86.4 cGy/h does not significantly increase the cumulative
incidence of mortality due to metastatic melanoma. It should be noted that it is
difficult to interpret the effects of apical doses and dose rates in isolation as there
are weak positive correlations between the tumour height and scleral dose (R =
0.92), between the tumour height and scleral dose rate (R = 0.65), and between the
tumour height and scleral BED (R = 0.87). The apical BED is a function of both
the apical dose and dose rate, but the dose to the apex and the treatment time vary
independently and so the apical BED is only weakly correlated with the apical dose
(R = 0.75) and with the apical dose rate (R = 0.61). The patient age at time of
treatment shows no significant correlation with either baseline characteristics of the
tumour or with any treatment parameters, so the effect of age on patient survival is
more easily assessed.
Coefficient (β) eβ SE(β) z p
Age 0.057 1.058 0.022 2.620 0.009
Apical dose rate 0.15 1.16 0.07 2.067 0.039
Apical BED -0.33 0.72 0.14 -2.457 0.014
Table 5.5: Estimated model parameters from initial Cox model for covariates with
coefficients significantly different from zero.
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5.3 Local recurrence of tumour
Local recurrence was detected in 26 out of 114 patients (23%) at the time of analysis.
The estimated 5-year recurrence rate (and 95% confidence interval) is 19% (15 % -
24%). The cumulative incidence function of recurrence is illustrated in Figure 5.2.
Figure 5.2: Cumulative incidence of local recurrence, as estimated using the
competitive-risks model.
The new Cox model estimated a statistically significant coefficient only for the
scleral dose (parameters shown in Table 5.6). An increase of the scleral dose by 1
Gy is expected to reduce the probability of local recurrence by 2.5% per month.
The 5-year cumulative mortality rates for the patients grouped according to scleral
doses were 16% and 26% for the high and low dose groups respectively. The associ-
ated functions are illustrated in Figure B.9 in the Appendix. A Gray test indicated
that the cumulative mortality rates were not significantly different between the two
groups. As discussed above, interpretation of the relationship between local recur-
rence and scleral dose is confounded by the correlation between scleral dose and
tumour height, but it is reasonable to expect that a higher scleral dose would result
in greater damage to the blood vessels supplying the tumour and therefore greater
probability of local control.
The 5-year failure of local control estimated for this cohort is higher than the
10.3% (95% confidence interval 8.0 - 13.2%) estimated using the KM method for the
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Coefficient (β) eβ SE(β) z p
Scleral dose -0.026 0.975 0.009 -2.983 0.0029
Table 5.6: Estimated model parameters for initial Cox model (only parameters for
covariates with statistically significant coefficients are shown).
COMS trial [30]. The KM method will likely underestimate the incidence of failure in
the presence of competing risks, but the report does not describe the mortality rate
due to unrelated causes, nor any means of accounting for competing risks. However,
the higher rate of recurrence observed here than in the COMS is unsurprising as the
doses to the tumour apex (and therefore the scleral doses) considered in this study
are lower than those delivered in the COMS.
The majority of local recurrences (24 out of the 26 patients, or 92%) were treated
by enucleation; the other two cases were treated with a second plaque brachytherapy
procedure. Although COMS showed that local recurrence is only weakly associated
with reduced survival [30], treatment of local recurrence by enucleation can be con-
sidered a failure of the secondary aim of plaque brachytherapy; preservation of the
globe.
5.4 Visual outcome
The visual outcome of 35 out of 114 (31%) treatments was regarded as poor. Of the
35 patients with poor visual outcome, 29 (83%) were enucleated. Nineteen of these
enucleations were performed because of tumour recurrence and ten were performed
because of poor visual outcome and / or a painful globe. A model of the cumulative
incidence of poor visual outcome indicated that the estimated 5-year cumulative
incidence of poor visual outcome (and 95% confidence interval) is 28% (24 - 33%).
The cumulative incidence function of poor visual outcome is shown in Figure 5.3.
The figure shows a sharp initial rise of the number of treatments classed as having
poor visual outcome, which levels out around 2 years after treatment. The median
time between treatment and enucleation is 18 months. Visual acuity may improve
over the first few months after treatment due to healing of trauma associated with the
operation, but regression of the tumour may not be observed for many months after
radiation therapy is performed. The mean latency of detecting tumour regression in
the subset of these patients studied by Sia et al. was 12 months. The chronology of
poor visual outcome is consistent with the observation from COMS that the majority
(68%) of enucleations in the COMS were performed within 3 years of treatment.
The cumulative incidence of poor visual acuity in the treated eye estimated here
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Figure 5.3: Cumulative incidence of poor visual outcome, as estimated using the
competitive-risks model.
is considerably less than the cumulative incidence observed in COMS, which found
that 3 years after treatment 45% of patients had poor visual outcome, compared
with 10% at the start of treatment. The lower risk of poor visual outcome for the
patients included in this study is also likely due to the lower doses delivered here
than in COMS, as it is expected that the lower doses will lead to both reduced prob-
ability of normal tissue complications and reduced probability of tumour control. By
contrast, the estimated 5-year cumulative incidence of poor visual outcome for the
non-treated eye was 1% (95% confidence interval 0.5% - 2%). The non-treated eye
will still receive a small radiation dose of the order of a few Gy, but for the pur-
pose of comparison it may be regarded as an indication of the risk of development
of poor visual acuity for reasons unrelated to plaque brachytherapy for the patient
demographic considered here.
The COMS did not explicitly examine the influence of scleral dose, nor scleral
dose rate, on the risk of poor visual outcome for the treatment, but greater baseline
height was found to strongly predict poor visual outcome [31]. The dose to all extra-
and intra-ocular normal tissue will increase with baseline height of the tumour owing
to the inverse relationship between dose and distance from the radiation sources to
the tumour apex so, as expected, the risk of adverse effects to structures at risk
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increases with increasing dose to these structures. The COMS also identified that
shorter distance between the tumour base and the foveal avascular zone (FOZ)
increases the risk of poor visual outcome. Patients at high risk of poor visual
outcome had tumours greater than 5 mm in height and less than 2 mm from the
FOZ [31, 15].
The dose to a point 2 mm from the edge of a tumour of 5 mm height was calcu-
lated for each of the COMS standard plaques, assuming a minimum 2 mm margin at
the edge of the tumour. The doses for each plaque, calculated using both the COMS
formalism and the updated formalism, are shown in Table 5.7. From these calcula-
tions, it was surmised that a poor visual outcome may be expected if the dose to the
FOZ exceeds 115 Gy (as calculated with the updated formalism). Unfortunately,
the COMS results did not include any information about radiobiological doses, nor
of dose volume histograms for the FOZ, so more detailed analyses of threshold doses
for the region cannot be performed.
COMS plaque diameter (mm) COMS dose (Gy) Line-source dose (Gy)
10 145 115
12 130 100
14 112 85
16 90 68
18 75 57
20 63 47
Table 5.7: The dose to a point 2 mm from the edge of the tumour base for a tumour
5 mm in height and with a diameter 4 mm smaller than that of the plaque. Doses are
calculated using both the COMS formalism and the updated line-source formalism
that incorporates the effects of the Silastic carrier and the gold shell.
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The survival rates observed in this trial were the same as those reported for
the COMS. However, the 5-year cumulative incidence of local recurrence is approx-
imately twice that found for the COMS and as most of these recurrences were
addressed by enucleation the higher rate of recurrence represents both a potentially
unnecessary loss of the globe for many of these patients in addition to the greater
demand on surgical resources and greater imposition on the patient. If the dose to
the prescription point of 75.7 Gy, as calculated with a line source model and inclu-
sion of scattering and attenuation effects of the eye plaque, were adopted here then
the likelihood of survival may be maximised by optimising the treatment regime so
that the BED to the tumour apex is maximised. Figure 6.1 shows the BED to the
tumour apex as a function of treatment time for a prescribed dose of 75.7 Gy. The
BED is maximised for shorter treatment times and therefore at higher dose rates to
both the apex and sclera.
Figure 6.1: The BED as a function of treatment time for a prescribed dose of 75.7
Gy.
The analysis here has ignored the BED to the normal tissue within and sur-
rounding the globe. For a specific dose to the tumour apex, the BED to normal
tissue will also increase with reduced treatment time but, as no information was
collected about the location of the plaque relative to critical structures, the physical
and radiobiological doses to nearby organs at risk of radiation damage could not be
estimated. However, the relationship between the BED to normal tissue and treat-
ment time is likely to show a more rapid decrease of BED with increasing treatment
time. Figure 6.3 shows the BED for both the tumour and normal tissue, calculated
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by assuming that the (α/β) ratios of the tumour and normal tissue are 10 Gy and 3
Gy respectively, that the recovery constant µ is the same for both the tumour and
normal tissue, and that the dose to the normal structure is 55 Gy whereas the dose
to the tumour is 75.7 Gy. It is expected that the BED curve for normal tissue will
intercept the BED curve for the tumour at a certain treatment time, but the point of
intersection will depend on the dose to the normal tissue. Further, the relationship
between the doses, both physical and radiobiological, to the nearby normal tissue
and the risk of adverse effects is unknown as the doses to normal critical structures
were not evaluated here.
The physical dose to the FOZ will be dictated by the proximity of the tumour
to the FOZ but the radiobiological dose to this region will also be influenced by the
dose rate. The probability of a successful outcome, defined as both patient survival
and preservation of vision, may be optimised by considering a dual approach to
treatment delivery. The survival probability may be maximised for patients at low
risk of poor visual outcome by prescribing a shorter treatment time and therefore
achieving a higher BED to the tumour. For patients at high risk of poor visual
outcome, a longer treatment time could be selected to reduce the BED to the FOZ.
Using Plaque Simulator, the distance between the central axis of the plaque and the
115 Gy isodose line were calculated for different combinations of plaque size used
at Royal Perth Hospital and of tumour height, assuming a prescription of 76 Gy to
the tumour apex. The distances are illustrated as a function of tumour height for
the 10 mm, 12 mm, 15 mm and 20 mm diameter plaques in Figure 6.2.
As no information about radiobiological doses to the FOZ is available, exact rec-
ommendations for treatment times cannot be made. However, the possible treatment
times must be constrained so that the BEDs of both the tumour and structures at
risk are within acceptable limits. The range of dose rate of 0.37 Gy/h to 0.93 Gy/h,
as calculated with the updated dosimetry data, used by COMS would correspond
to treatment times of 204 hours to 81 hours. Further, practical concerns, such as
staff and theatre availabilities, patient comfort and the radiation safety of the staff,
patient and carers should also be considered and it will be the responsibility of the
radiation oncology and ophthalmology staff to optimise the treatment outcome in
the context of such concerns when deciding an appropriate treatment regimen.
Finally, this study of eye plaque dosimetry has not considered an important cause
of gross treatment error; the air kerma strength of the sources. Appropriate quality
assurance procedures must be followed for the construction of eye plaques. An ideal
system would include both quantitative and qualitative assessment of the three-
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Figure 6.2: Distance between the central axis of the plaque and the 115 Gy isodose
line (as calculated using the line-source formalism) as a function of tumour height
for a treatment delivering 76 Gy to the tumour apex.
dimensional dose distribution for an eye plaque, but, in absence of such a system,
measurement of the air kerma strength of individual sources would be appropriate.
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Figure 6.3: The BED for the tumour (solid line) and normal structure (dotted line)
as a function of treatment time for a dose of 75.7 Gy to the tumour apex and of 55
Gy to a nearby normal structure.
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Figures A.1, A.2, A.3 and A.4 show the dose rates along the central axis of the
10 mm, 12 mm, 15 mm and 20 mm diameter plaques respectively when fully loaded
with seeds of 1.0 mCi activity, as calculated with the COMS (dashed line) and line-
source (solid line) formalism. The differences between the dose rates calculated with
each formalism are also shown (circles).
Figure A.1: Central axis dose rate for 10 mm plaque loaded with 1.0 mCi seeds.
Figure A.2: Central axis dose rate for 12 mm plaque loaded with 1.0 mCi seeds.
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Figure A.3: Central axis dose rate for 15 mm plaque loaded with 1.0 mCi seeds.
Figure A.4: Central axis dose rate for 20 mm plaque loaded with 1.0 mCi seeds.
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B.1 Competing-risks survival
Figure B.1 shows the scaled Schoenfeld residuals against transformed time for the
disease-specific Cox model of mortality. Figure B.5 shows index plots of the dfβ
residuals, calculated from changes to the estimated coefficients for age, apical dose
rate and apical BED when individual observations are deleted. Figure B.3 shows
the martingale residuals versus covariates and the martingale residuals plus the
component values of the covariates versus covariates.
Figure B.1: Scaled Schoenfeld residuals for the Cox model of (disease-specific) sur-
vival against transformed time (in months) for the patient age at time of treatment
(age), apical dose rate (apexdr) and apical BED (apexbed). The solid line is a
smoothing-spline fit to the data and the dashed lines represent the ± 2σ" band
around the fit.
B.2 Local recurrence
Figure B.4 shows the scaled Schoenfeld residuals against transformed time for the
Cox model of local recurrence. Figure B.5 shows index plots of the dfβ residuals,
calculated from changes to the estimated coefficients for age, enucleation and scleral
dose when individual observations are deleted. Figure B.6 shows the martingale
residuals versus covariates and the martingale residuals plus the component values
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Figure B.2: Index plots of dfβ for the disease-specific Cox model of time to mortality
on age, apical dose rate and apical BED. The dashed line represents dfβ = 0 (no
change due to deletion of observation).
of the covariates versus covariates.
B.3 Cumulative incidence functions
B.3.1 Cumulative incidence of mortality
The cumulative incidence functions predicted for high and low values of the apical
dose rate and the apical BED are shown in Figures B.7 and B.8 respectively.
B.3.2 Cumulative incidence of local recurrence
The cumulative incidence function predicted for the high and low values of the scleral
dose are shown in Figure B.9.
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Figure B.3: Plots of martingale residuals versus covariates (top row) and of martin-
gale residuals plus component values of covariates versus covariates (bottom row)
for the disease-specific Cox model of mortality. The dashed lines on the residual
plots indicate the horizontal axis (Residual = 0) and the solid lines represent the
smoothed spline fits. The dashed lines on the component-plus-residual plots indicate
the linear least-squares fit to the data and the solid lines are fitted by local linear
regression.
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Figure B.4: Scaled Schoenfeld residuals for the Cox model of local recurrence against
transformed time for the patient age at time of treatment (age), enucleation and
scleral dose (sclerad). The solid line is a smoothing-spline fit to the data and the
dashed lines represent the ± 2σ" band around the fit.
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Figure B.5: Index plots of dfβ for the Cox model of time to local recurrence on age,
enucleation and scleral dose. The dashed line represents dfβ = 0 (no change due to
deletion of observation).
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Figure B.6: Plots of martingale residuals versus covariates (top row) and of martin-
gale residuals plus component values of covariates versus covariates (bottom row) for
the Cox model of local recurrence of the tumour. The dashed lines on the residual
plots indicate the horizontal axis (Residual = 0) and the solid lines represent the
smoothed spline fits. The dashed lines on the component-plus-residual plots indicate
the linear least-squares fit to the data and the solid lines are fitted by local linear
regression.
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Figure B.7: Cumulative incidence functions for mortality for high (dashed line) and
low (solid line) values of the apical dose rate.
Figure B.8: Cumulative incidence functions for mortality for high (dashed line) and
low (solid line) values of the apical BED.
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Figure B.9: Cumulative incidence functions for local recurrence for high (dashed
line) and low (solid line) values of the scleral dose.
